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Chapter 1: Introduction 
 
1 
1 Introduction 
1.1 Nucleic acid-based therapy 
Nucleic acid-based therapy holds tremendous promise in the treatment of many genetic and 
acquired diseases by delivering therapeutic nucleic acids into patients. In general it exhibits 
the possibility to compensate a genetic defect or to indirectly mediate a therapeutic effect 
(“gain of function”) or to silence target genes, which are either pathogenic or essential for cell 
viability (“loss of function”).  
Meanwhile more than 1500 clinical trials on nucleic acid-based therapeutics have been or still 
are conducted. The indications cover as diverse fields as inherent genetic diseases (e.g. cystic 
fibrosis, severe combined immunodeficiency (SCID)) and acquired diseases (e.g. infectious 
diseases, neuropathological diseases). Nevertheless cancer therapy is the main focus (> 60%) 
(1). Therapeutic effects in cancer treatment are mainly achieved by knocking out genes that 
facilitate tumor growth, or by introducing therapeutic genes that – when expressed – 
antagonize tumor growth or cause apoptosis in tumor cells (2, 3). 
Standard gene therapy is based on the integration of genes into the target cells genome to 
correct or mediate the expression of certain proteins. New approaches mainly utilize small 
interfering RNA (siRNA), which can be used to posttranscriptionally silence protein 
expression by specific degradation of messenger RNA (mRNA) (4). The mechanism of siRNA 
mediated gene silencing is adopted from the naturally occurring phenomenon of RNA 
interference. This is based on double stranded RNA (dsRNA) molecules which are proposed 
to function as a mechanism for regulation of gene expression on the posttranscriptional level. 
While delivery of dsRNA to mammalian cells provokes an interferon response and apoptosis, 
small synthetic dsRNA, so called siRNA does not evoke such effects but is equally effective 
(5). Within the cytosol siRNA is cleaved into single strands and the antisense strand is 
incorporated into the RNA induced silencing complex (RISC). If the nucleotide sequence of 
the antisense strand resembles a sequence within the mRNA of a target gene, this mRNA is 
cleaved in the middle by RISC. Cleavage of the mRNA leads to reduction of translation and 
therefore silencing of the targeted gene (6) (Figure 1). 
This technology became increasingly important not only in research due to the possibility to 
create specific knock-down systems for basic research and determination of new therapeutic 
targets, but also due to its impact as a new therapeutic tool in nucleic acid-based therapy. 
Consequently in 2006 Andrew Fire and Craig Mello won the Nobel Prize for their work on 
RNA interference in Caenorhabditis elegans which was published in the year 1998 (7). 
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Figure 1: Processing of dsRNA to effective siRNA. 
(A) In the cytosol dsRNA is incorporated into RISC. 
(B) The dsRNA is spliced into single strands. 
(C) The sense strand is degraded. 
(D) The antisense strand remains incorporated in RISC. 
(E) Complementary mRNA sequences are bound by the antisense strand. 
(F) This guides RISC to splice the target mRNA. The corresponding protein is silenced. 
 
Despite these promising data nucleic acid-based therapy still holds a lot of challenges. Nucleic 
acids naturally are highly hydrophilic and therefore cannot permeate lipid cell membranes. 
Additionally they are subject to fast degradation by nucleases mainly in the blood stream (8-
11). Only for a few applications, like intramuscular injection, electroporation or hydrodynamic 
injection, naked pDNA led to effective gene transfection (12-15), naked siRNA based therapy 
was successfully shown in the treatment of age related macula degeneration in mice (16) and 
has already been applied in humans in clinical trials (17). But for the broad range of 
indications nucleic acids have to be transported to their target tissues. 
1.2 Delivery of nucleic acids 
Generally, nucleic acid delivery systems can be divided into two main categories: viral vectors 
and synthetic transfer systems. Viral vectors are most commonly used in clinical trials due to 
their high transfection ability (1). Nevertheless their performance is hampered by toxicity, 
potential of insertional mutagenesis, immunogenicity, low transgene loading size, high costs 
and low adaptability of design (18, 19). These problems can be overcome by the development 
RISC
RISC
ds RNA
siRNA
sense and 
antisense strand
degraded sense strand
antisense strand
incorporated into RISC
target mRNA
splicing of dsRNA into 
single strands 
siRNA guides RISC to 
target mRNA
median splicing of mRNA
(A)
(B)
(C) (D)
(E)
(F)
RISC
 
Chapter 1: Introduction 
 
3 
of synthetic gene delivery systems. Such delivery systems are designed to provoke less 
immunogenicity, to offer a higher loading capacity and to be easily and rather cheaply 
synthesized. Additionally they implicate the advantage to be easily adaptable to specific needs. 
On the other hand the major drawback of synthetic vectors is their limited efficacy compared 
to viral vectors after in vivo application. Amongst the synthetic nucleic acid delivery systems 
the most distinguished subgroups are liposomal formulations and cationic polymers (20, 21). 
Liposomal formulations are based on cationic lipids, which are amphiphilic molecules. This 
structure leads in aqueous solutions after condensation of the positively charged head-group 
with the negatively charged nucleic acids to spontaneous assembles into nanospheric 
lipoplexes thereby protecting the nucleic acids from degradation (22). Like cationic lipids, 
cationic polymers show as well high potential to condense nucleic acids. In the line of cationic 
polymers polyethylenimine (PEI) has an outstanding position due to its superior transfection 
efficacy (23-25). Nevertheless its toxicity, which is caused by the positive surface charge, the 
non-degradability of the polymer and a variety of undesired, unspecific interactions with the 
biological environment has to be considered (26, 27). Accordingly in the field of cationic 
polymers as nucleic acid delivery systems the major challenge is to decrease toxicity and 
simultaneously hold or even increase transfection efficacy compared to the gold standard PEI. 
Peracute toxicity in vivo is mainly caused by the surface charge of the polyplexes leading 
already in the blood stream either to aggregation with erythrocytes causing embolism or to 
uptake by macrophages and therefore rapid removal (26, 28-30). Toxicity and rapid clearance 
can be diminished by shielding of the polyplexes e.g. with polyethylenglycol (PEG), or 
reduction of their surface charge (31-33). Acute toxicity is also due to accumulation of the 
polymers in reticular organs such as lung or liver because of their non-degradability (34). This 
problem can be overcome by using biodegradable polymers, which ideally exhibit high 
stability in the extracellular surrounding whereas after delivering their payload they degrade to 
non-toxic metabolites in the intracellular environment (35, 36).  
To enhance the transfection efficacy at least two bottle necks have to be taken into 
consideration. These are specific uptake of the polyplexes by the targeted cells and endosomal 
release. To allow for specific cellular uptake, polyplexes have on the one hand to be stable in 
the blood stream (37, 38), on the other hand targeting ligands are needed to enhance the uptake 
by specific tissues (39). Ligands are as diverse as antibodies (40), peptides (41), transferrin 
(42), sugars (43), mannuronic acid (44), folate (45) and growth factors such as EGF (46). For 
effective endosomal release disruption of the endosomal membrane is necessary. Some 
polycations (e.g. PEI) naturally possess considerable buffering properties below the 
physiological pH, leading to the so called “protone sponge effect” (47). Briefly explained 
buffering of the protons by PEI leads to endosomal accumulation of hydrated chloride ions, 
which subsequently results in osmotic effects leading to swelling and disruption of the 
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endosome (48). As another possibility to mediate endosomal escape the polymer is conjugated 
to endosomolytic peptides. Those peptides are either adopted from naturally occurring 
sequences (e.g. peptides derived from viruses) (49, 50), from the bee venom (51, 52) or 
artificially synthesized (e.g. GALA) (53).  
 
 
Figure 2: Optimized delivery of nucleic acids from application to action side. 
(A) After systemic application polyplexes are distributed by the bloodstream. Leaky 
tumor vasculature favours extravasation into extracellular environment. Shielding and 
diminished surface charge hinder undesired interaction with blood components or 
aggregation. 
(B) By local application polyplexes directly reach the extracellular environment. 
(C) Polyplexes bind to the cells. Targeting ligands mediate a selective uptake by target 
cells. 
(D) Polyplexes cause disruption of the endosomal membrane. siRNA cargo is released 
into the cytosol. 
(E) siRNA is further processed by RISC (see: Figure 1) 
 
The following sections will focus on synthetic vectors used in the present work. For more 
details on recent developments in the design of nucleic acid delivery systems see Schaffert et 
al. (54) and Meyer et al. (55).  
1.2.1 OEI – HD1 
The polymer is synthesized using oligoethylenimine 800 Da (OEI) and 1, 6-
hexanedioldiacrylate (HD) as a linker, resulting in a biodegradable polymer with branched 
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structure (56). To enhance the specific uptake by tumor cells and provide shielding, OEI-HD1 
was further modified adding Transferrin (Tf) as a targeting and shielding ligand (Tf-OEI-
HD1). It was shown that a mixture of OEI-HD1 with Tf-OEI-HD1 (w/w: 90/10) is able to 
promote a specific silencing of the targeted gene in tumor cells in vitro and in vivo without 
unspecific toxicity (57). This formulation is subsequently referred to as OEI-HD1/Tf-OEI-
HD1 (90/10). 
1.2.2 bPEI Succ 10 
bPEI Succ 10 is synthesized by succinylation of 10% of the amines of branched PEI 25 kDa 
(bPEI). This modification decreases the positive charge of the polymer resulting in high 
transfection efficacy for siRNA and less toxicity in murine neuroblastoma cells (Neuro 2a) in 
vitro compared to PEI (33).  
1.2.3 Tf-PLL-DMMAn-Mel-ss-siRNA 
Tf-PLL-DMMAn-Mel is an analog of the poly-L-lysine (PLL) conjugate described in Meyer 
et al. (58) containing Transferrin (Tf) and melittin peptide (Mel) acylated with 2,3-
dimethylmaleic anhydride (DMMAn). The modification with Tf mediates an effective 
shielding and a receptor targeting function, and the melittin peptide masked by DMMan 
provides pH-sensitive endosomolytic properties. Extracellular stability is generated by 
covalent attachment of the siRNA. Therefore this conjugate exhibits high biocompatibility and 
transfection efficacy in vitro. 
1.2.4 PLL50-PEG-DMMAn-Mel / PLL185-PEG-DMMAn-Mel 
PLL50-PEG-DMMAn-Mel and PLL85-PEG-DMMAn-Mel were synthetized as PLL-PEG-
DMMAn-Mel (58), but PLL molecules with a defined chain length (PLL 50 and PLL 185) 
were used. The numbers (50 and 185) thereby refer to the number of lysines in the PLL chain. 
Thereby the polydispersity of the polymers is diminished and the biocompatibility is 
enhanced. 
1.3 Assessment of nucleic acid transfer systems 
Modification of nucleic acid transfer systems in order to decrease toxicity and increase 
efficacy requires an appropriate assessment of performance. First tests include evaluation of 
toxicity and efficacy in vitro. As a next step toxicity, distribution and efficacy of nucleic acid 
transfer systems are assessed in vivo. In vivo applicable methods bear much more challenges 
as in vitro methods.  They should allow for consecutive measurements as well as fast and easy 
analysis, be highly sensitive and specific, facilitate statistically significant results and not at 
least be compatible with animal welfare. Taken together literally no in vivo method so far 
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fulfils all these demands. The following chapters focus on in vivo/ex vivo methods with a 
special emphasis on methods for efficacy testing. 
1.3.1 Toxicity  
Preclinical toxicity testing of potential drug candidates for application in clinical trials is 
excessive. It includes observation of acute and chronic toxicity as well as reproductive and 
teratogenic toxicity (59). Nevertheless first toxicity tests mainly concentrate on peracute and 
acute adverse reactions. In case of polycationic transfer systems those are predominantly 
caused by interference of the polyplexes with blood components, liver or lung tissue (26, 28-
30, 34). To predict the interaction of polyplexes with blood components, ex vivo erythrocyte 
leakage assays and blood aggregation assays are performed (36, 58). Affection of liver and 
lung tissue can be visualized by histopathology of the respective organs. Light microscopic as 
well as fluorescence microscopic pictures can reveal pathological changes such as adverse 
metabolism, apoptosis or necrosis (34, 57). Measurement of the blood levels of certain liver 
enzymes such as aspartate aminotransferase (AST or SGOT) and alanine aminotransferase 
(ALT or SGPT) illustrate toxic damage to liver cells (57). Additionally in small rodents 
decreased body weight as a consequence of inappetence is a fast and easy remarkable 
parameter. 
1.3.2 Distribution 
Assessment of drug distribution patterns is an essential step to forecast possible side as well as 
desired effects. It is mainly performed by tagging the drug with a reporter molecule, which can 
be easily detected. Well established methods are based on fluorescent dyes or quantum dots 
(Fluorescence Imaging) or radioisotopes (Positron Emission Tomography (PET), Single 
Photon Emission Computed Tomography (SPECT)) (60, 61). Additionally determination of 
drug levels in body fluids (e.g. blood, serum, urine, faeces) is facilitated. Nevertheless drug 
distribution must not be confused with drug efficacy. Even accumulation of the drug in certain 
tissues does not necessarily implicate efficacy of the drug at this specific side. For example 
polycations as nucleic acid transfer vector systems are typically distributed over the blood 
stream throughout the whole body when administered intravenously. Often their side of 
accumulation differs substantially from the side of action depending on the targeting, thereby 
making it necessary to equally prove efficacy as well as distribution (34, 62).  
1.3.3 Efficacy 
In case of nucleic acid delivery the provoked effect that has to be proven is for DNA the 
expression of a gene resulting in the translation of the encoded protein, and for siRNA the 
specific silencing of a gene by interaction with the corresponding mRNA resulting in a stop of 
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protein translation. Therefore efficacy in delivering nucleic acids can for DNA as well as 
siRNA be shown on the protein as well as on the nucleic acid level. 
One of the most sensitive techniques for nucleic acid detection and quantification currently 
available is Real Time Quantitative Polymerase Chain Reaction (rtQPCR) (63). Messenger 
RNA is reverse transcribed to cDNA. The specific amplification of cDNA by thermostable 
DNA polymerase is assessed by fluorescence measurements over the exponential phase of the 
PCR. The fluorescence signal is generated by using fluorescent dyes that intercalate with 
double-stranded DNA or sequence specific DNA oligonucleotide probes that fluorescence 
when being cleaved due to the nuclease activity of DNA polymerase. Therefore the 
fluorescence signal is proportional to the increasing amount of DNA copies. Values of target 
mRNA are normalized to mRNA values of a housekeeper, that is unaffected by the therapy.  
In the present study, beside Luciferase, Ran was used as target gene. It served as a positive 
control, because it was already used successfully in our lab as a target for siRNA mediated 
silencing in vivo (57). Ran protein was recently identified from an RNAi based screen as 
possible target in cancer therapy, as its knockdown with siRNA leads to apoptosis (64). It is a 
small GTPase and has been implicated in a large number of nuclear processes including 
regulation of nuclear transport and formation and organisation of the microtubule network (65, 
66).  
Despite of being a very valuable tool for efficacy testing the above mentioned method bears 
the disadvantage of relying on single point evaluations ex vivo. This implicates that drug 
kinetics within the same animal cannot be displayed. This consequently leads to higher 
numbers of animals per experiment, which is problematic due to ethical as well as commercial 
reasons and moreover does not result in the same level of confidence. With in vivo imaging 
methods these disadvantages can be egalised.There are several methods available at the 
moment that meet the demands discussed above, for example computer tomography (CT), 
magnetic resonance imaging (MRI), positron emission tomography (PET), single photon 
emission tomography (SPECT) and fluorescence as well as bioluminescence imaging (67, 68). 
CT imaging relies on the different absorption of X-rays by various tissues, thereby allowing 
for high anatomical resolution imaging (but with relatively low soft tissue contrast) of small 
animals (69, 70). MRI is based on nuclear magnetic resonance. Unpaired nuclear spins, which 
are usually hydrogen atoms, align themselves when placed in a magnetic field. They thereby 
form a net effect called magnetic dipole. The dipoles can be disturbed by using a radio-
frequency pulse. When the system thereafter relaxes back to its equilibrium state, the 
relaxation time corresponds to the physicochemical environment. Due to the differences in 
magnetic susceptibility of certain tissues MR images with high spatial resolution, versatile 
contrasts and clear tissue delineation can be obtained. However a drawback lies within the 
long acquisition and processing time and the low contrast (CT) or sensitivity (MRI), 
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respectively. In nuclear acid-based therapy CT and MRI can be used to measure therapeutic 
effects, e.g. the volume of a treated tumor (71). Further effort has been made to improve the 
contrast (72) and the sensitivity (73-79). PET relies on isotopes emitting positrons (e.g. 15O, 
13N, 11C, 18F). The positrons undergo annihilation with nearby electrons, thereby resulting in 
two gamma-rays. Those gamma-rays are subsequently detected, converted into visible light 
and displayed as a PET image. In contrast, isotopes for SPECT imaging (e.g. 123I, 99mTc) 
directly emit gamma-rays. This technique makes it less sensitive and specific as PET but on 
the other hand bears the advantage of a longer half-life of the isotopes accompanied by lower 
costs. For PET as well as SPECT the imperative to apply radiation to the animal is a major 
drawback and has to be taken into consideration. Marker genes that have been used with 
PET/SPECT imaging in nucleic acid-based therapy include the thymidine kinase transgene 
from HSV (HSV-tk) and its mutant version HSV-sr39tk (80-83), which trap their radiolabeled 
substrates in the cells by phosphorylation. Also other enzyme-based reporter systems (84, 85) 
and extracellular receptors for transport of radiolabeled molecules into the cell have been 
facilitated (86). Another widely used marker gene is the human sodium iodine symporter 
(human NIS) (87, 88), which allows for PET as well as SPECT imaging by mediating cellular 
uptake of 123I-iodine or 99mTc respectively. 
Despite the numerous successful experiments that have been performed with the imaging 
methods described above, in vivo optical imaging is more convenient, because it is highly 
sensitive, relatively cheap, does not rely on radiation and allows for rapid analysis due to its 
fast acquisition and processing time. Additionally the use of the same marker gene in vitro and 
in vivo is possible, which is beneficial. Taken together optical imaging fulfils nearly all 
demands for a suitable in vivo screening system. Still it has to be mentioned that also optical 
imaging methods have their challenge which mainly lies in attenuation of the signal with 
increasing signal depth. Optical imaging can be divided into two categories, fluorescence 
imaging and bioluminescence imaging, and in general employs the detection of light emission 
by a charge-coupled device (CCD) camera. 
In fluorescence imaging light is emitted by a fluorochrome after excitation by an external light 
source of a different wavelength. For this purpose there are several fluorochromes available. 
The most prominent are green fluorescent protein (GFP) with an emission wavelength of 509 
nm and its variants, e.g. eGFP, which has a longer emission wavelength and is brighter than 
the wildtyp (89, 90); red fluorescent protein (RFP) (emission wavelength: 574 nm) and its 
variants offer greater stability and longer emission wavelength (91, 92).  
Within nucleic acid-based therapy direct expression of these reporter genes in target tissue or 
fusion of the reporter to a therapeutic gene are possible opening the way for a broad spectrum 
of experimental designs (93-95). Nevertheless there are restrictions to fluorescence imaging 
which originate from a high signal-to-noise ratio due to tissue autofluorescence and absorption 
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by hemoglobin. To overcome this problem fluorochromes emitting light of a wavelength 
longer than 600 nm should be used (96), hence tissue penetration can be maximised and 
autofluorescence diminished (97, 98). In this context the use of quantum dots (QD) which 
fluorescence brightly up to the near infrared (NIR) spectrum is beneficial (99). But then the 
toxicity of QD is discussed diversely (100).  
In contrast to fluorescence imaging, bioluminescence imaging creates virtually no background 
light noise as light output is restricted to the expression sites of the luciferase enzymes. These 
enzymes can catalyze the emission of photons. A major challenge is given by the fact that this 
enzymatic reaction is depending on the availiability of the substrate and in certain cases also 
on the presence of other co-factors and/or oxygen. Nevertheless bioluminescence imaging has 
evolved into the most employed technique for detection of effective nucleic acid transfer, 
including the transfer of siRNA.  
1.4 In vivo bioluminescence imaging for siRNA efficacy studies 
As mentioned above successful siRNA delivery in living subjects will consequently lead to the 
knockdown of the targeted protein. Protein depletion can be assessed directly by 
bioluminescence imaging, if the luciferase enzyme itself or a protein that influences the 
expression of luciferase (e.g. by promoting transcription of luciferase gene) is targeted, or 
indirectly, if the siRNA mediates death of luciferase expressing cells.  
Heidel et al. showed reduction of tumor growth by targeting ribonucleotide reductase M2 
subunit in transgenic neuroblastoma xenografts with siRNA (101). In order to test the 
functionality of this siRNA in vivo, a cotransfection was performed by high pressure tail vein 
coinjection of pDNA encoding for a fusion protein of ribonucleotide reductase M2 subunit and 
luciferase together with the siRNA. This injection technique leads by pressure induced 
reversion of the blood flow within the liver to highly efficient delivery of nucleic acids to the 
hepatocytes. Bioluminescence imaging thereafter revealed the silencing of the fusion protein. 
Pre-treatment of luciferase transgenic neuroblastoma cells with this siRNA before injection 
into the mice mediated a reduction in tumor growth. High pressue tail vein coinjection was as 
well used to compare the efficacy of siRNA and shRNA (102). Coinjection of pDNA and 
siRNA was also conducted in a mouse skin model. Herein siRNA targeted a mRNA 
bicistronically fused to luciferase mRNA (103). Although a significant siRNA mediated effect 
could be visualized by bioluminescence imaging, coinjection of pDNA encoding for the target 
gene together with the siRNA does not represent settings of gene therapy in human beings. 
Therefore the animal models and test procedures have to be further adapted to more closely 
mirror therapeutic situations.  
Bisanz et al. developed a metastatic prostate xenograft mouse model and showed growth 
retardation of luciferase expressing bone metastases by intratumoral injection of siRNA 
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targeting alpha-v integrin (104). By establishing a subcutaneous luciferase transgenic 
neuroblastoma model in A/J mice, Bartlett et al. for the first time proved successful siRNA 
delivery to tumor tissue by directly targeting luciferase (62, 105). This working group also 
identified parameters within treatment that influence the outcome of siRNA delivery studies 
(106). Thereby it was shown that there are multiple parameters to be considered to obtain 
optimized results, such as dosage regimen of siRNA, cell doubling time and half-life of the 
target protein. Beside these treatment derived factors there are even more aspects to taken into 
account that originate from bioluminescence imaging itself. As mentioned above 
bioluminescence imaging relies on the quantification of photons. These photons are emitted 
due to an enzymatic reaction which depends not only on amount, character and activity of the 
enzyme, but also on the abundance of substrate, oxygen and energy. Additionally the detection 
of emitted photons can be hampered by tissue specific attenuation due to absorption and 
scattering of light by haemoglobin or melanin (107). The intensity of photons in the visible 
spectrum, such as that produced by luciferases, are attenuated approximately 10-fold per cm of 
tissue. 
Coming along with the importance of luciferases as reporter enzymes there are several 
different luciferases available. The most commonly used luciferase is derived from Photinus 
pyralis (firefly luciferase). It oxidizes its substrate, luciferin, to oxyluciferin thereby producing 
light with a broad emission spectrum and a peak at approximately 560 nm (108). This reaction 
depends on energy (ATP) and oxygen. Click beetle green and click beetle red luciferases, 
which were isolated from Pyrophorus plagiophtalamus and subsequently optimised for 
different wavelengths (544 and 611 nm, respectivly) rely on the same enzymatic reaction 
(109). At 37 ° C, and taking attenuation into account, light emission from click beetle and 
firefly luciferases is comparable.  
Luciferases from Renilla reniformis and Gaussia princes react with a different substrate, 
coelenterazine, thereby producing light with an emission peak at approximately 480 nm (110-
113). Albeit being oxygen dependent, this reaction is independend of ATP. The utility of 
renilla and gaussia luciferases for in vivo imaging is hampered by their short wavelength and 
higher background signals caused by auto-oxidation of coelenterazine. On the other hand their 
independency of energy as well as the fact, that gaussia luciferase is secreted, makes them 
interesting tools for imaging studies. Therefore currently efforts are undergone to create renilla 
and gaussia luciferases with longer wavelengths (113). In addition to the enzymes, lux operons 
from bacteria, such as Photorhabdus luminescence, emit blue light without the need for an 
exogenous substrate. This effect has been used to monitor bacterial infections by 
bioluminescence imaging. However there has been insufficient research to determine if 
transfer of this operon to mammalian cells would be possible. 
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Alongside with optimization of the wavelength there is high effort put into alteration of the 
enzymes stability. Firefly luciferase has a half-life of approximately 3 – 4 hours, which should 
not limit the quantitative bioluminescence determination when performed as daily 
measurements. Nevertheless, destabilization motifs (e.g. PEST or tetra-ubiquitin) are used to 
shorten the half-life of luciferase (114, 115). Another approach is the identification of 
luciferase mutants with improved pH, thermal, and/or proteolysis resistance (116-118).  
Beside the luciferase enzyme itself, biodistribution and pharmacology of the substrates are 
critical parameters and have to be standardized for reproducible quantification of 
bioluminescence. 
In case of luciferin typically 150 mg/kg body weight are applied systemically by 
intraperitoneal injection. It has been reported that this concentration does not always lead to a 
maximal bioluminescence signal. Higher luciferin concentrations as well as local application 
increased the signal output dramatically with dependence on anatomic localization of the 
reporter (119). This is further supported by the finding, that 125I-labeled luciferin is not 
distributed equally throughout the animal body with lower amounts in tissues such as bone, 
heart, skeletal muscle or brain (120). This result might however partly rely on the label itself. 
Coelenterazine typically is injected directly into the circulation, either through tail vein or 
intracardiac injection. This route of application is more cumbersome and additionally the 
substrate distribution is hampered by active transport out of the tissue (121, 122). In addition 
to the above mentioned auto-oxidation these are severe drawbacks for this substrate and 
consecutively for renilla and gaussia luciferase. 
Another parameter that strongly influences the measurements is the kinetic of 
bioluminescence. While renilla and gaussia luciferase produce flash kinetics with a peak 1 – 2 
minutes after injection (110), kinetic is prolonged for firefly and click beetle luciferase with 
peaks after approximately 10 – 20 minutes. Therefore models that are based on renilla or 
gaussia luciferase are more likely to be affected by variations in timing between substrate 
injection and image acquisition. But even measurements using firefly and click beetle 
luciferase depend on exact time management.  
Independently of the utilized luciferase further modifications are possible to adapt 
bioluminescence imaging to special needs. An often performed option is the control of 
luciferase expression by a physiological cellular pathway. An example that was as well 
facilitated in the present work is the hypoxia inducible factor (HIF) pathway. 
1.4.1 Integration of luciferase into the HIF-pathway 
The transcription complex hypoxia inducible factor (HIF) plays a central role in the 
maintenance of the oxygen (O2) homeostasis, which is essential for cell survival (123). HIF is 
tightly regulated in an O2-dependent manner by hydroxylation of one of the three HIF subunits 
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(HIF1, HIF2, and HIF3) (124, 125). In well oxygenated cells (normoxia), the hydroxylation of 
two proline residues by the HIF-prolyl hydroxylases (prolyl hydroxylase domains (PHDs)) 
allows the specific recognition and polyubiquitination by the von Hippel-Lindau protein 
(pVHL) E3–ligase complex, leading to proteasomal degradation (126). Moreover, the 
hydroxylation of an asparagine residue by the factor inhibiting HIF (FIH) prevents binding of 
the coactivator p300/CBP and hence blocks HIF transcriptional activity (127). In contrast, 
restricted O2 availability by preventing HIF hydroxylation results in HIF stabilization and 
activation of the HIF transcriptional complex. Like FIH, the PHDs belong to the super family 
of iron- and 2-oxoglutarate-dependent dioxygenases, which, by using O2 as a cosubstrate, 
provide the molecular basis for their O2-sensing function (128). In mammalian cells, three 
PHD isoforms have been identified (PHD1, PHD2, and PHD3) and have been shown to 
hydroxylate HIF1 (129). It was reported that PHD2 has a dominant role, as it is the rate-
limiting enzyme that sets the low steady-state level of HIF1 in normoxia (130, 131) . 
 
 
Figure 3: HIF pathway under normoxic or hypoxic conditions. 
(A) – (D) Normoxic conditions. (E) – (F) Hypoxic conditions. 
(A) Proline residues of HIF1 alpha subunit are hydroxylated by PHD enzymes in an 
oxygen and iron dependent reaction. 
(B) Hydroxylated HIF1 alpha is recognized by VHL 
(C) and subsequently polyubiquitinated. 
(D) Ubiquitination leads to degradation of HIF1 alpha subunit. 
(E) HIF1 alpha subunit translocates into the nucleus. 
(F) HIF1 alpha and HIF 1 beta form a dimer, which activates transcription of HIF 
dependent genes such as erythropoietin (EPO), vascular endothelial growth factor 
(VEGF), inducible nitric oxide synthase (iNOS) or lactate dehydrogenase (LDH). 
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Luciferase can be set under the control of the HIF-pathway by different approaches. Gillespie 
et al. for example used tumor cells expressing luciferase under the control of a modified 
thymidine kinase promoter. Therefore it was consistently expressed in a hypoxia- and HIF-1–
dependent manner (132). By targeting HIF1 with siRNA mediated treatment they were able to 
show a substantially decrease of luciferase by bioluminescence imaging in a tumor mouse 
model. 
Another approach is the employment of a fusion protein of HIF and luciferase (133). 
Applicability of this construct for hypoxia detection and tests of small molecule PHD 
inhibitors was shown in vitro as well as in vivo.  
Taken together these data implicate that with bioluminescence imaging highly sensitive 
images of siRNA mediated protein knockdown can be obtained. But for every single purpose a 
highly specific animal model and measurement protocol has to be tailored, which exactly 
meets the needs.  
 
1.5 Aim of this thesis 
The imperative to specifically tailor a mouse model for successful evaluation of siRNA 
delivery was pointed out above. Accordingly, the aim of this thesis is the generation, 
characterization and utilization of a mouse model for in vivo evaluation of siRNA delivery by 
synthetic vectors to tumor tissue. As bioluminescence imaging is the most advantageous in 
vivo imaging method it was therefore chosen for the experimental design. Beside the 
traditional method that relies on a reduction of bioluminescent signal as the readout (reducible, 
negative readout system) the development of a method that shows an induction of 
bioluminescent signal in case of successful siRNA delivery (inducible, positive readout 
system) was aimed. 
The negative readout transgenic tumor cell clones were established based on some subtypes of 
firefly luciferase that differed in expression intensity and protein half-life (Luc, Luc+, Luc2). 
Such transgenes are designed to lead to increasing expression intensities. In order to decrease 
the enzyme half-life, Luc2 was equipped with two degradation sequences (CL1-PEST) (134). 
The positive readout transgenic tumor cell clones rest upon a fusion construct of one of the 
oxygen depending domains (ODD) of HIF1alpha and firefly luciferase (ODD Luc). Thereby 
luciferase expression is directly controlled by the HIF pathway (133).  
As tumor cell line the murine neuroblastoma cell line Neuro 2a was chosen. Neuro 2a cells are 
known to overexpress the Tf-receptor, which allows for proper cell targeting by Tf-containing 
siRNA particles, and to reliably form well vascularized subcutaneous tumors in A/J as well as 
SCID mice, which is beneficial for systemic delivery (35, 57, 135). Additionally good 
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correlation between in vitro and in vivo tests was anticipated because these cells have as well 
been used for in vitro experiments.  
The newly derived transgenic cell clones were characterized in vitro and in vivo by evaluation 
of bioluminescent signal and growth kinetics. Additionally the tumor mouse models had to be 
specifically optimized according to the demands of siRNA delivery studies. This was done by 
ruling out the influence of certain parameters on the bioluminescent readout. The best 
performing tumor mouse models were selected for further implementation in siRNA delivery 
studies. In addition to the ODD luciferase transgenic tumor mouse model transgenic mice 
expressing ODD luciferase in all tissues were utilized for siRNA treatment. SiRNA treatments 
were performed in vitro as well as in vivo.  
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2 Material and Methods 
2.1 Materials 
Materials were purchased/prepared as stated below. 
2.1.1 Bacterial culture 
LB-plates - Bacto-Trypton (AppliChem, Darmstadt, Germany): 10g 
- Yeast Extract (AppliChem, Darmstadt, Germany): 5g 
- NaCl (Merck, Darmstadt, Germany): 5g 
- Agar (AppliChem, Darmstadt, Germany): 15 g 
- ad 1 liter with aqua bidest 
LB-medium - Bacto-Trypton (AppliChem, Darmstadt, Germany): 10g 
- Yeast Extract (AppliChem, Darmstadt, Germany): 5g 
- NaCl (Merck Darmstadt, Germany): 5g 
- ad 1 liter with aqua bidest 
Ampicillin SIGMA-Aldrich (Steinheim, Germany) 
TfbI - 30 mM KAc (Merck, Darmstadt, Germany): 0.29 g 
- 50 mM MnCl2 (Merck, Darmstadt, Germany): 0.99 g 
- 100 mM KCl (Merck, Darmstadt, Germany): 0.75 g 
- 10 mM CaCl2 (Merck, Darmstadt, Germany)): 0.11 g 
- 15% Glycine (Merck, Darmstadt, Germany): 15 mL 
- ad 100 mL with aqua bidest 
- adjust on pH 5,8 with acetic acid 
TfbII - 10 mM Na MOPS (Fluka, Steinheim, Germany): 0.21 g 
- 75 mM CaCl2 (Merck, Darmstadt, Germany): 0.83 g 
- 10 mM KCl (Merck, Darmstadt, Germany)): 0.075 g 
- 15% Glycine (Merck, Darmstadt, Germany): 15 mL 
- ad 100 mL with aqua bidest 
Comp. E. coli (Dh5 alpha) - incubate 50 µL DH5alpha in 1 mL LB medium without 
antibiotics overnight 
- cultivate 1 mL of overnight culture in 100 mL medium 
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until OD550 reaches 0.5 
- centrifuge with 3500 rpm at 4 °C for 5 minutes 
- resuspend pellet in 40 mL icecooled TfbI buffer 
- incubate on ice for 20 minutes 
- centrifuge with 2500 rpm at 4 °C for 5 minutes 
- resuspend pellet in 4 mL TfbII 
 
2.1.2 Molecular biology 
2.1.2.1 Vector cloning and amplification 
T4 DNA ligase Promega (Mannheim, Germany) 
T4 DNA ligation buffer Promega (Mannheim, Germany) 
Restriction buffers New England BioLabs (Ipswich, U.S.A.) / Promega 
(Mannheim, Germany) 
BSE New England BioLabs (Ipswich, U.S.A.) / Promega 
(Mannheim, Germany) 
EndoFree plasmid kits 
(Mini/Maxi/Mega/Giga) 
Quiagen (Hilden, Germany) 
10x TBE elektrophorese 
buffer 
- Tris base (SIGMA-Aldrich, Steinheim, Germany): 108 g 
- Boric acid (Merck, Darmstadt, Germany): 55g 
- ad 700 mL with aqua bidest  
- 0.5 M EDTA (SIGMA-Aldrich, Steinheim, Germany)): 40 
mL 
- adjust with NaOH (VWR International, Darmstadt, 
Germany) on pH 8  
- ad 1 liter with aqua bidest 
Agarose Invitrogen (Karlsruhe, Germany) 
Ethidiumbromide SIGMA-Aldrich (Steinheim, Germany) 
DNA-marker Peqlab Biotechnologie (Erlangen, Germany) 
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2.1.2.1.1 Restriction enzymes 
Apa L1 BioLabs (Ipswich, U.S.A.) 
Nhe I  BioLabs (Ipswich, U.S.A.)/Promega (Mannheim, Germany) 
Hind III BioLabs (Ipswich, U.S.A.)/Promega (Mannheim, Germany) 
Avr II BioLabs (Ipswich, U.S.A.) 
Sal I BioLabs (Ipswich, U.S.A.) 
Bgl II  Promega (Mannheim, Germany) 
 
2.1.2.2 Western blot 
Blotting membrane (PVDF) Macherey-Nagel (Düren, Germany) 
BSA Invitrogen (Karlsruhe, Germany) 
Pierce protein detection kit Thermo Scientific (Bonn, Germany) 
1.5 M Tris pH 8.8 - Tris base (SIGMA-Aldrich (Steinheim, Germany)) 
- add 70 mL Aqua bidest 
- correct on pH 8.8 
- ad 100 mL with aqua bidest 
Acrylbis (30%) Bio-Rad (München, Germany) 
SDS (10%) - SDS (Roth, Karlsruhe, Germany)): 10g 
- ad 100 mL with aqua bidest 
TEMED Promega (Mannheim, Germany) 
APS (10%) - Ammoniumpersulfat (SIGMA-Aldrich, Germany): 1 g 
- ad 100 mL with aqua bidest 
Precision plus protein dual 
color standards 
Bio-Rad (München, Germany) 
Methanol ACROS (Geel, Belgium) 
Transferbuffer - 25 mM Tris base (Fluka , Steinheim, Germany): 3.03 g 
- 192 mM Glycine (Merck, Darmstadt, Germany): 14.4 g 
- solve in 400 mL aqua bidest 
- add 100 mL Methanol (ACROS, Geel, Belgium) 
10 x TBS buffer - Tris base (Fluka, Steinheim, Germany): 24.2 g 
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- NaCl (VWR International, Darmstadt, Germany): 80 g 
- solve in 800 mL aqua bidest 
- corrcect pH with HCl (SIGMA-Aldrich, Steinheim, 
Germany) on pH 7.6 
- ad 1 liter with aqua bidest 
Blocking buffer - 10 x TBS Buffer: 15 mL 
- milk powder: 7.5 g 
- aqua bidest: 135 mL 
- Tween-20 (SIGMA-Aldrich, Steinheim, Germany): 150 µL 
Washing buffer - 10 x TBS Buffer: 100 mL 
- aqua bidest: 900 mL 
- Tween-20 (SIGMA-Aldrich, Steinheim, Germany): 1mL 
ECL spray Upstate Cell Signaling Solutions (Billerica, U.S.A.) 
 
2.1.2.2.1  Antibodies 
antiVHL antibody Cell Signaling (Frankfurt a.M., Germany) 
anti alpha tubulin antibody SIGMA-Aldrich (Steinheim, Germany) 
2nd antibodies Vector Laboratories (Burlingame, U.S.A.) 
 
2.1.2.3 PCR 
Sequences  in 5’ – 3’ direction are stated following the purchasing company. 
oligo-dT-primers  MWG Biotech (Eberberg, Germany) 
DNA extraction kit  
(Wizard Promega) 
Promega (Mannheim, Germany) 
PCR buffer Promega (Mannheim, Germany) 
Q-solution Promega (Mannheim, Germany) 
MgCl2 Promega (Mannheim, Germany) 
d´NTPs Promega (Mannheim, Germany) 
High pure RNA tissue kit Roche Diagnostics (Mannheim, Germany) 
Primers (Luciferase) Roche Diagnostics (Mannheim, Germany) 
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L:TGAGTACTTCGAAATGTCCGTTC 
R:GTATTCAGCCCATATCGTTTCAT 
Primers (Ran) Roche Diagnostics (Mannheim, Germany) 
L:ACCCGCTCGTCTTCCATAC 
R:ATAATGGCACACTGGGCTTG 
Lysis buffer Roche Diagnostics (Mannheim, Germany) 
Transcriptor high fidelity 
cDNA synthesis kit 
Roche Diagnostics (Mannheim, Germany) 
Random hexamer primers Roche Diagnostics (Mannheim, Germany) 
Universal probe library 
hydrolysis probe #2/#29 
Roche Diagnostics (Mannheim, Germany) 
Mouse GADP gene assay Roche Diagnostics (Mannheim, Germany) 
Mouse BACT gene assay Roche Diagnostics (Mannheim, Germany) 
 
2.1.3 Cell culture 
Murine neuroblastoma Neuro 
2a cells 
LGC Standards (ATCC CCI-131) 
Neuro 2a eGFP Luc cells Neuro 2a cells stably expressing a fusion protein of eGFP and 
Photinus pyralis luciferase were constructed in our lab by 
Jaroslav Pelisek. 
DMEM 1 g glucose - DMEM, 4.5 g Glucose/L, with L-Glutamin, without 
NaHCO3 (Biochrom, Berlin, Germany): 10.15 g  
- NaHCO3  p.A.: 3.7 g 
- ad 1 liter with aqua bidest 
OptiMEM Invitrogen (Karlsruhe, Germany) 
Penicillin-Streptomycin Biochrom (Berlin, Germany) 
FBS Invitrogen (Karlsruhe, Germany) 
L-alanyl-L-glutamine Biochrom (Berlin, Germany) 
G418 Invitrogen (Karlsruhe, Germany) 
Puromycin SIGMA-Aldrich (Steinheim, Germany) 
Hygromycin SIGMA-Aldrich (Steinheim, Germany) 
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Cell culture plates TPP (Trasadingen, Switzerland) 
Cell culture flasks TPP (Trasadingen, Switzerland) 
TE Biochrom (Berlin, Germany) 
PBS - Phosphat buffered saline (Biochrom, Berlin, Germany): 
9.55g 
- ad 1 liter with aqua bidest 
Clon ring SIGMA-Aldrich (Steinheim, Germany) 
Rich cream SIGMA-Aldrich (Steinheim, Germany) 
Amphotericin B SIGMA-Aldrich (Steinheim, Germany) 
 
2.1.4 In vitro/in vivo transfection experiments 
HBS - Hepes (Biomol, Hamburg, Germany): 2.38 g 
- ad 300 mL with aqua bidest 
- adjust with NaOH (VWR International, Darmstadt, 
Germany) on pH 7.1 
- NaCl (VWR International, Darmstadt, Germany): 4.383 g 
- check pH, ad 500 mL with aqua bidest 
HBG - Hepes (Biomol, Hamburg, Germany): 2.38 g 
- ad 300 mL with aqua bidest 
- correct with NaOH (VWR International, Darmstadt, 
Germany) on pH 7.1 
- Glucose-Monohydrat (Merck, Darmstadt, Germany):  
27.5 g 
- check pH, ad 500 mL with aqua bidest 
HBS 0,5 HBS/HBG: 1/1 
Recombinant luciferase Promega (Mannheim, Germany) 
Luciferase cell culture lysis 
reagent 
Promega (Mannheim, Germany) 
Luciferin Promega (Mannheim, Germany) 
LAR - 1 M Glycylglycin (Merck, Darmstadt, Germany):  2 mL 
- 100 mM MgCl (Carl Roth, Karlsruhe, Germany): 1mL 
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- 500 mM EDTA (SIGMA-Aldrich, Steinheim, Germany): 
20µL 
- DTT (SIGMA-Aldrich, Steinheim, Germany): 50.8 mg 
- ATP (Roche, Mannheim, Germany): 27.8 mg 
- Coenzym A (SIGMA-Aldrich, Steinheim, Germany):  
0.5 mL 
- ad 100 mL with aqua bidest 
- adjust with  NaOH (VWR International, Darmstadt, 
Germany) on pH 8 – 8.5 
Deferoxamine SIGMA-Aldrich (Steinheim, Germany) 
Isoflurane ® cp Pharma (Burgdorf, Germany) 
Bepanthene® Roche (Grenzach-Whylen, Germany) 
Ketavet® 100 mg/mL Pfizer, Pharmacia GmbH (Karlsruhe, Germany) 
Rompun® 2% Bayer Vital GmbH (Leverkusen, Germany) 
Syringes Heiland (Hamburg, Germany) 
Needles Heiland (Hamburg, Germany) 
Isotonic sodiumchloride 
solution 
B Braun Melsungen AG (Melsungen, Germany) 
   
2.1.4.1 Synthetic siRNA vectors 
Linear PEI 22 kDa PEI (22 kDa) was synthesized by acidcatalysed deprotection 
of poly(2-ethyl-2-oxazoline) (50 kDa, Aldrich) in analogous 
form as described in Brissault et al. (136) and is also available 
from Polyplus Transfections (Strasbourg, France). 
OEI-HD 1 OEI-HD 1 was synthesized by crosslinking of 
oligoethylenimines 800 (OEI) with 1,6-hexanedioldiacrylate 
(HD) as described in Kloeckner et al. (56).  
bPEI Succ 10 PEI Succ 10 was synthesized by succinylation of LPEI as 
described in Zintchenko et al. (33). 
Lipofectamine Invitrogen (Karlsruhe, Germany) 
Tf-PLL- DMMAn- Mel / PLL- DMMan-Mel was synthesized by modification of PLL 
according to Meyer et al. (58). 
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PLL50-PEG-DMMAn-Mel / 
PLL185-PEG-DMMAn-Mel 
Tf was integrated (Tf-PLLDMMAn-Mel) or PLL of a defined 
chain length (PLL50, PLL185) were used (PLL50-PEG-
DMMAn-Mel, PLL185-PEG-DMMAn-Mel). 
 
2.1.4.2 siRNA 
Sequences of the sense strand in 5’ – 3’ direction are stated following the purchasing 
company. 
 
Control #3 Eurofins MWG Operon (Ebersberg, Germany) 
AUGUAUUGGCCUGUAUUAGUUdTdT 
Luc Eurofins MWG Operon (Ebersberg, Germany) 
CUUACGCUGAGUACUUCGAdTdT 
VHL #50  Ambion (Darmstadt, Germany) 
#50: GGACUUCUGGUUAACCAAAdTdT 
PHD2 Eurofins MWG Operon (Ebersberg, Germany) 
GAACUCAAGCCCAAUUCAG dTdT 
 
2.1.4.3 Plasmids 
pCMV Luc Plasmid Factory (Bielefeld, Germany).  
The plasmid design is described in Plank et al. (137). 
pC1 The plasmid was kindly provided by the working group of R. 
Haase, LMU Munich, München, Germany). 
pCDNA3 ODD Luc / 
pCDNA3 Luc 
Both plasmids were kindly provided by the working group of 
W. G. Kaelin, Harvard Medical School, Boston, U.S.A..  
The plasmid designs are described in Safran et al. (133). 
pGL3 contr. Promega (Mannheim, Germany) 
pGL4.16 Promega (Mannheim, Germany) 
 
2.1.4.4 Laboratory animals 
A/JOlaHsd (A/J) Harlan-Winkelmann (Borchen, Germany) 
NMRI-nu (nu/nu) Janvier (Le Genest-St-Isle, France) 
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FVB.129S6-Gt(ROSA)26Sor 
<t mice (FVB ODD Luc) 
CharlesRiver Laboratories (JacksonLab) (Kisslegg, Germany) 
FVB N/J (FVB) CharlesRiver Laboratories (JacksonLab) (Kisslegg, Germany) 
 
2.1.5 Instruments 
Luminometer Lumat LB 
9507 
Berchtold (Tuttlingen, Germany) 
Luminometer Centro LB 960 Berchtold (Tuttlingen, Germany) 
Tecan SpectraFlour Plus Tecan (Crailsheim, Germany) 
IVIS Lumina Caliper Life Science (Rüsselsheim, Germany) 
Shaver Philishave C486 Philips (Hamburg, Germany) 
Caliper Digi-Met Peisser (Gammertingen, Germany) 
PX2 Thermal Cycler Thermo electron corporation (Karlsruhe, Germany) 
Light Cycler 480 Roche Diagnostics (Mannheim, Germany) 
 
2.1.6 Software 
MikroWin 2000 Berchtold (Tuttlingen, Germany) 
ImageJ  National Institute of Health (Bethesda, U.S.A.) 
Graph Pad Prism 4 software  Graph Pad Software (San Diego, U.S.A.) 
Living Image 3.0 Caliper Life Science (Rüsselsheim, Germany) 
ProbeFinder 2.44 software Roche Diagnostics (Mannheim, Germany) 
 
2.2 Amplification of plasmids 
All plasmids used were amplified in heat shock transformed E.coli. Competent E. coli were 
defrosted on ice before plasmid DNA was added. Thereafter the bacterial solution was kept on 
ice for 30 minutes, put into a 42° C water bath for 90 seconds and stored again on ice for 2 
minutes. After heat shock transformation overnight colonies were grown using LB plates with 
ampicillin as selection pressure. Positive colonies were further amplified by overnight 
culturing in LB medium and plasmid DNA was purified using the EndoFree Plasmid Kits. 
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2.3 Cloning of the SV40 promoter into the pGL4.16 plasmid 
The SV40 promoter was excised from the pGL3 control plasmid using Hind III and Nhe I as 
restriction enzymes and ligated into the pGL4.16 plasmid, which had been cut with the same 
enzymes, using T4 DNA ligase in an overnight reaction. (Restriction digest and ligation 
according to manufacturers protocols.) Thereafter the new vector was transferred into E.coli, 
propagated and the plasmid was isolated. Bacterial clones expressing the desired 
pGL4.16SV40 plasmid were identified by restriction digest of purified plasmid DNA with Avr 
II as restriction enzyme. (Restriction digest was performed according to manufacturers 
protocol.) Correctly ligated constructs are cut twice, whereas empty pGL4.16 plasmid is cut 
only once. Positive colonies were further amplified and pGL4.16SV40 plasmid was harvested 
(see: 2.2). The functionality of this newly generated plasmid was proven by transfection of 
Neuro 2a cells (see: 2.6.2). 
2.4 Western blot   
Proteins were extracted from wildtype Neuro 2a cells as described in 2.6.3. 50 µg protein per 
lane was separated by SDS-PAGE under reducing conditions. Proteins were then transferred 
on a PVDF membrane and blocked with 5 % fat-free milk powder for one hour at room 
temperature. Immunostaining was performed using primary murine VHL antibody diluted 
1:1000 in blocking buffer over night at 4°C according to manufacturers protocol and 
peroxidase labelled anti-rabbit-IgG diluted 1:2000 in blocking buffer as the secondary 
antibody for two hours. VHL protein was visualized using ECL western blotting detection 
spray. In addition, to allow for normalization of protein expression, detection of the 
housekeeping protein alpha-tubulin was performed using primary murine antibody for one 
hour following incubation with anti-mouse HRP-secondary antibody for another hour. For 
quantification, VHL protein expression of each sample was normalized for the expression of 
the housekeeping protein alpha-tubulin by quantification using ImageJ. 
2.5 RtQPCR  
In order to prepare the tumor tissue samples for rtQPCR analysis, the samples were frozen in 
liquid nitrogen and crushed using a mortar. Twenty mg of the crushed tissues were incubated 
for 10 min with 400 µL lysis buffer. RNA was isolated using the High Pure RNA Tissue Kit 
according to the manufacturers protocol. RNA concentration was determined by absorbance at 
260 nm. Two hundred ng of total RNA was used as template for cDNA synthesis using the 
Transcriptor High Fidelity cDNA Synthesis Kit according to manufacturer’s protocol. For the 
reverse transcriptase reaction Random Hexamer Primers were used. For polymerase chain 
reaction 5 µL of cDNA dilution 1:5 in aqua bidest was used and PCR was performed with 
primers for luciferase or Ran together with Universal ProbeLibrary hydrolysis probe # 29 (for 
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Luc) or # 2 (for Ran) respectively. Primers and probes were designed using the ProbeFinder 
2.44 software. Furthermore, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-
Actin (BACT) were used as internal standard. Dual-colour Multiplex real-time analysis was 
performed on the Light Cycler 480, data were acquired using the advanced relative 
quantification method. PCR was performed at 95°C for 10 minutes denaturation prior to 
amplification by 45 cycles with 10 seconds (sec) at 95 °C, 30 sec at 60 °C, 1 sec at 72°C and a 
final cooling step of 30 sec at 40°C. 
2.6 Cell culture  
2.6.1 Maintenance of cultured cells 
All cultured cells were grown at 37 °C in 5% CO2 humidified atmosphere. Wildtype murine 
neuroblastoma Neuro 2a cells and primary ODD Luc fibroblasts (preparation: see: 2.6.5) were 
cultured in DMEM (1 g/L glucose) supplemented with 10% FCS and 1% Penicillin-
Streptomycin. Transgenic murine neuroblastoma Neuro 2a cells were cultured in DMEM (1 
g/L glucose) supplemented with 10% FCS, 1% Penicillin-Streptomycin and selection 
antibiotic (Neuro 2a eGFP Luc, Neuro 2a Luc, Neuro 2a Luc+, Neuro 2a ODD Luc: G418 
(2,25 mg/mL medium); Neuro 2a  Luc2: Hygromycin (1,5 mg/mL medium)). 
2.6.2 Luciferase reporter gene assay 
For the evaluation of expression efficacy of the different luciferase encoding plasmids the 
luciferase activity was measured in 96-well plates with pCMV Luc as a reference. 24 h prior 
to transfection Neuro 2a cells were seeded at a density of 1x104 cells in 200 µL medium per  
well. At the time point of transfection cells reached a confluency of 60% to 80%.  
Transfections were performed by using polyplexes of LPEI and 200 ng plasmid DNA at a w/w 
ratio of 0.8/1 in HBS 0.5. Medium was exchanged against 90 µL fresh medium, 10 µL of 
polyplex solutions were added directly to the cells and after 4 h medium was exchanged 
against 100 µL fresh one. After 24 hours, cells were washed once with PBS and were 
subsequently lysed with 50 µL of 1:5 diluted cell culture lysis reagent per well.Luciferase 
activity was determined from 20 µL samples of the lysates using the luciferase assay system at 
the luminometer. Two nanograms of recombinant luciferase correspond to 107 light units.  
2.6.3 VHL protein expression in Neuro 2a 
For the evaluation of the expression of VHL, wildtype Neuro 2a cells were grown in cell 
culture flasks up to 70% confluence, cells were washed once with ice cooled PBS and were 
subsequently lysed with 200 µL of 1:5 diluted cell culture lysis reagent containing protease 
inhibitor cocktail. Thereafter a Western Blot was performed (see: 2.4). Protein extracted from 
murine liver tissue served as a positive control. 
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2.6.4 Creation of transgenic luciferase expressing Neuro 2a cell clones 
To create monoclonal transgenic cell clones expressing different types of photinus pyralis 
luciferase, wildtype Neuro 2a cells were seeded in 96-well plates at a density of 1x103 cells in 
200 µL medium. 
At the time point of the first transfection cells reached a confluency of 10%. 
24 and 72 h after seeding cells were transfected using LPEI polyplexes (w/w ratio of 0.8/1 in 
HBS 0.5). 200 ng plasmid DNA per well were used. Medium was exchanged against 90 µL 
fresh medium, 10 µL of polyplex solutions were added directly to the cells and after 4 h 
medium was exchanged against 100 µL fresh one. 24 h after the second transfection selection 
antibiotic was added to the medium (concentration as indicated in 2.6.1). After 3 days under 
selection pressure wells were washed carefully with PBS to remove dead cells and 
supplemented with selection antibiotic containing medium. Wells were allowed to reach 70% 
confluency before splitting of each well into two wells. One well was checked for gene 
expression (see: 2.6.2), the other one remained as backup.  
The backups of those wells tested positive for luciferase expression were maintained further 
and finally all wells containing cells transgenic for the same type of luciferase were pooled to 
get one polyclonal cell line. 
This cell line was subsequently splitted to a very low density (approximately 5 cells/mL 
medium) in 96-well-plates in order to generate wells containing only a single cell to derive a 
cell clone from. Those cell clones were maintained in the wells until they reached a 
confluency of 70 %, thereafter transferred to cell culture flasks for further maintenance and 
finally seeded in 96-well-plates at a density of 1x104 cells and after 24 h checked for 
expression efficacy (see: 2.6.2). 
2.6.5 Preparation of primary ODD Luc expressing fibroblasts 
A newborn heterozygous FVB ODD Luc donor mouse was sacrificed under sterile conditions 
by cervical dislocation. Small pieces of the ear were sliced, subsequently washed in 70% 
ethanol for several times and finally put in a cell culture dish containing DMEM (1 g/L 
glucose) supplemented with 10% FCS, 2% Penicillin-Streptomycin and Amphotericin B (0.25 
µg/mL).Fibroblasts were grown at 37 °C in 5% CO2 humidified atmosphere until the separated 
from the ear tissue. During the first splitting ear tissue was removed carefully. Thereafter 
primary fibroblasts were maintained as described in 2.6.1. 
2.6.6 Luciferase gene silencing   
To check on the functionality of the newly created transgenic cell clones cells were seeded in 
96-well plates using 1x104 cells per well 24 h prior to siRNA delivery. At the time point of 
treatment cells reached a confluency of 60% to 80%. Polyplexes containing 0.25 or 0.5 µg 
siRNA per well and the indicated amount of polymers respectively were prepared in 20 mL 
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HBG per well and after a complexion time of 30 minutes added to cells in 80 µL medium. 
Lipoplexes containing 0.25 or 0.5 µg siRNA per well and the indicated amount of 
Lipofectamine were prepared in 20 mL OptiMEM per well, after a complexion time of 30 
minutes added to cells in 80 µL serum free medium, and after 4 hours medium was exchanged 
against 200 µl fresh serum containing medium. 24 to 72 h after treatment medium was 
removed and cells were lysed in 50 µL cell lysis reagent in order to measure the luciferase 
activity as described in 2.6.2. 
2.7 Animal experiments 
Animal experiments were performed according to guidelines of the German law of protection 
of animal life and were approved by the local animal experiments ethical committee. Mice 
were kept under specific pathogen free conditions in isolated ventilated cages with 5 animals 
per cage. Cages were equipped with wood shaving litter, a wooden rodent tunnel, cellulose 
bedding and a mouse house. Autoclaved standard breeding chow and water were provided ad 
libitum. A 12 h day/night cycle, 21° celsius room temperature and 60% humidity were kept. 
Mice were allowed to adapt to the housing conditions for at least one week before experiments 
were started. 
2.7.1 Characterization of subcutaneous tumor mouse models 
A/J mice, female, 6 – 10 weeks old were used (n = 10 per group). 
Tumor cells were grown in cell culture as described above, despite being kept in antibiotic free 
medium for one week prior to injection. To harvest the cells they were trypsinated, washed 
several times with PBS and diluted in ice cooled PBS at a concentration of 106 cells per 150 
µL. One day prior to tumor cell injection the injection side was shaved using a Philishave 
C486 shaver. One hundred and fifty µL of the cell suspension were injected subcutaneously at 
one or both flanks of the mice. Tumor size was measured every second day by caliper and 
determined as a*b*c (a = length, b = width, c = height). Bioluminescence signal was measured 
every second day by a CCD camera (IVIS Lumina). Mice were anaesthetized by inhalation of 
isoflurane in oxygen (2.5% (v/v)) at a flow of 1 liter/min. Thereafter 100 µL luciferin solution 
(c = 60 mg/mL) were injected intraperitoneally and allowed to distribute for 10 minutes prior 
to bioluminescence measurement. Results were evaluated using the Living Image 3.0 
software. 
2.7.2 siRNA delivery experiments 
2.7.2.1 Polyplex mediated siRNA delivery  
For these experiments A/J mice, female, 6 – 8 weeks old were used. Subcutaneous Neuro 2a 
Luc, Neuro 2a Luc+, Neuro 2a Luc2, Neuro 2a eGFP Luc and Neuro 2a ODD Luc tumors 
Chapter 2: Material and Methods 
 
28 
respectively (at one or at both flanks) were set as described in 2.7.1. Two days prior and up to 
2 – 4 days after siRNA treatment tumor size and bioluminescence signal were measured every 
day as described in 2.7.1. When tumors reached a size of about 100 – 200 mm3 siRNA 
treatment was performed by intravenous or intratumoral injection of polyplexes. For rtQPCR 
readout tumors were explanted 1 – 4 days after the treatment and rtQPCR was performed as 
described in 2.5. 
For each experiment mice were separated into three groups (n = 5/7 per group): (i) animals 
treated with target (siLuc or siRAN) siRNA, (ii) animals treated with unspecific scrambled 
(siContr#3) siRNA and (iii) non-treated animals. 
Tf-PLL-DMMAn-Mel-ss-siRNA was applied in an amount corresponding to 0.625 or 1.250 
mg/kg body weight siRNA in 12,5 mL/kg body weight sterile HBG.  
OEI-HD/Tf-PEG-OEI/siRNA polyplexes were formed at the OEI-HD/siRNA w/w ratio of 
0.5/1 containing 10 % targeting Tf conjugate, and were applied at concentrations of 200 
µg/mL siRNA, 90 µg/mL OEI-HD and 10 µg/mL OEI conjugated to Tf-PEG in sterile HBG. 
The blended carrier in this case contained 43 µg/mL transferrin, i.e. 29 % transferrin by weight 
of total polymer.  
bPEI Succ 10/siRNA polyplexes were formed at the bPEI Succ 10/siRNA w/w ratio of 2/1, 
and were applied at concentrations of 200 µg/mL siRNA and 400 µg/mL bPEI Succ 10 in 
sterile HBG.  
PEI (22 kDa)/siRNA polyplexes were formed at the PEI (22 kDa)/siRNA w/w ratio of 1/1, and 
were applied at concentrations of 200 µg/mL siRNA and 200 µg/mL PEI (22 kDa) in sterile 
HBG.  
In case of OEI-HD/Tf-PEG-OEI, bPEI Succ 10 and PEI (22 kDa) polyplexes 2.5 mg/kg body 
weight siRNA were applied intravenously via the tail vein. Applications were repeated three 
times, every 24 hours. 
PLL50-PEG-DMMAn-Mel was formed at the PLL50-PEG-DMMAn-Mel/siRNA w/w ratio of 
1/1 and was applied at concentrations of 100 µg/mL siRNA and 100 µg/mL PLL50-PEG-
DMMAn-Mel in sterile HBG. PLL185-PEG-DMMAn-Mel was formed at the PLL185-PEG-
DMMAn-Mel/siRNA w/w ratio of 0.5/1 and was applied at concentrations of 200 µg/mL 
siRNA and 100 µg/mL PLL185-PEG-DMMAn-Mel in sterile HBG. 
2.7.2.2 Hydrodynamic siRNA delivery  
siRNA delivery to liver tissue was performed in FVB ODD Luc mice 
(heterozygous/homozygous), female and male, 10 – 16 weeks old, by high pressure tail vein 
injection (hydrodynamic delivery). 
Mice were separated into two groups: (i) animals treated with target (siPHD2) siRNA (n = 4), 
(ii) animals treated with scrambled (siContr.#3) siRNA (n = 2). Mice were placed into a 
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restraining device and anesthetized by inhalation of isoflurane in oxygen (2.5% (v/v)) at a 
flow of 1 liter/min. Intravenous injections were performed by injecting a siRNA solution (12.5 
µg /mL in isotonic sodiumchloride solution) in a volume corresponding to 12 % of the total 
body weight within approx. 5 seconds (this corresponds to 2.4 mL in case of 20 g body 
weight) using a 30 gauge needle (0.3 x 12 mm). 2 days prior and up to 4 days after 
hydrodynamic delivery the bioluminescence signal of the liver was measured as described in 
2.7.1. 
2.7.3 Implantation of tumor fragments 
As donor as well as recipient animals A/J mice, female, 6 – 8 weeks old were used. In donor 
mice Neuro 2a Luc+ tumors were set as described in 2.7.1. When tumors reached a size of 
approximately 400 mm3, donor animals were sacrificed, tumors were explanted, kept in 37 ° C 
PBS and sliced into 8 mm3 pieces. Recipient animals (n = 5) were shaved one day prior to 
implantation. At the day of implantation recipient mice were anaesthetized by intraperitoneal 
injection of 50 µl of a solution containing 38,5:23:38,5 Ketavet (c = 100 mg / ml): Rompun 
(2%): isotonic sodium chloride solution. When mice reached anesthesia stage III a dermal 
incision of 0,5 cm was set at one flank, and a tumor piece was implanted. The incision was 
closed using Epiglue. Bioluminescence measurements were performed every day for the first 9 
days and additionally on day 13 and 16 as described in 2.7.1. 
2.7.4 Transgenic cell injection into wildtype tumor tissue 
A/J mice, female, 6 – 8 weeks old were used (n = 5). Neuro 2a wildtype tumors were set as 
described in 2.7.1. When tumors reached a size of approximately 400 mm3, Neuro 2a Luc+ 
cells were prepared as described in 2.7.1, dissolved in PBS at a concentration of 1x106 cells 
per 50 µL and injected into the wildtype tumors. For injection mice were anaesthetized with 
isoflurane, which was administered by inhalation of isoflurane in oxygen (2.5% (v/v)) at a 
flow of 1 liter/min. Bioluminescence measurements were performed every day for 4 days as 
described in 2.7.1. 
2.7.5 Luciferin kinetic studies 
A/J mice, female, 6 – 8 weeks old were used. Neuro 2a Luc+ tumors were set as described in 
2.7.1.  
When tumors reached as size of approximately 100 – 200 mm3, bioluminescence imaging was 
started and performed every day for 5 days. Mice were separated into two groups (n = 5 per 
group): (i) animals injected intraperitoneally with luciferin solution, (ii) animals treated 
intravenously with luciferin solution. Animals of both groups received 100 µL luciferin 
solution (c = 60 mg/mL). Before luciferin injection mice were anaesthetized with isoflurane, 
which was administered by inhalation of isoflurane in oxygen (2.5% (v/v)) at a flow of 1 
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liter/min. Directly after luciferin application a sequence bioluminescence measurement was 
performed for 30 minutes (intravenously applied group) and 60 minutes (intraperitoneally 
applied group). 
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3 Results 
3.1 Generation of different monoclonal Luc transgenic Neuro 2a 
cells  
3.1.1 Cloning of plasmid GL4.16SV40 
The first aim of the present work was the construction of transgenic Neuro 2a cells stably 
expressing firefly luciferases that differ in expression intensity and half-life of the enzyme and 
are supposed to serve as a negative readout system for siRNA delivery. Additionally a 
luciferase based system should be created, that shows signal induction as positive readout for 
siRNA treatment. 
 
 
Figure 4: Structure of the newly synthesised pGL4.16SV40. 
 
Luc, Luc+ and Luc2 were selected as transgenes for a negative readout system as they have 
been designed to show increasing expression intensities. To address the aim of decreasing the 
enzyme half-life Luc2 was equipped with two degradation sequences (CL1-PEST). As 
transgene for a positive readout bioluminescent system a fusion of a HIF1alpha fragment 
(ODD) and Luc+ was chosen (ODD Luc). CMV and SV40 promoter were used, respectively. 
pC1 (encoding for Luc under CMV promoter), pCDNA3 Luc (encoding for Luc+ under CMV 
promoter) and pCDNA3 ODD Luc (encoding for ODD Luc under CMV promoter) were 
obtained as stated in 2.1.4.3. To obtain a suitable plasmid encoding for the CL1-PEST 
modified Luc2, the SV40 promoter sequence was excised from pGL3 control and ligated into 
pGL4.16 (Figure 4). 
           HindIII – 6206 – A’AGCT_T 
NheI – 5282 – G’CTAG_C 
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3.1.2 Evaluation of expression intensities of luciferase encoding plasmids 
The expression intensities of the different plasmids that were chosen for generation of stably 
transgenic Neuro 2a clones were evaluated by transient transfections prior to stable 
transfection. 
As a transfer vector PEI (22 kDa) was used at different N/P ratios (molar ratio of nitrogen in 
PEI to phosphate in the nucleic acid). As a positive control pCMV Luc (encoding for firefly 
luciferase under CMV promoter) was used. Results were evaluated by using the luciferase 
reporter gene assay (Figure 5). 
 
 
Figure 5: Expression intensities of luciferase encoding plasmids on Neuro 2a cells. 
PEI (22 kDa) was complexed with the luciferase encoding plasmids in the indicated N/P 
ratios. 200 ng pDNA per well were used. Black bars show pCMV Luc as a positive control. 
Measurements were performed with n = 8, mean values from three independend experiments 
and standard deviations are shown. 
 
As expected, Luc+ exhibited no difference in expression intensity compared to the positive 
control, which was reported to hold high values (137). Luc, which has not been optimized for 
high expression intensity, Luc2, which is designed to have a faster kinetic due to its 
degradation domains, and ODD Luc, which is permanently degraded under normoxic 
conditions, showed highly significant (p < 0.001, One-way-ANOVA) diminished expression 
intensities in comparison to Luc+. Interestingly ODD Luc exhibited significantly (p < 0.001) 
higher expression activity than Luc and Luc2. 
3.1.3 Expression intensities of  stably luciferase expressing Neuro 2a cell clones 
Stable transfections with the plasmids were performed by using synthetic vectors. After 
transfection cells were cultured under selection pressure and finally monocloned. The 
expression intensity of the untreated cell clones was determined by luciferase reporter gene 
assay (Table 1 –3).  
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Luc 
Clone number RLU / 10.000 cells 
# 1 46.756  
# 2 28.617 
 
Table 1: Luciferase expression intensity of Neuro 2a Luc cell clones. 
The clone that was used for further experiments is highlighted in grey. It is thereafter named 
Neuro 2a Luc. 
 
Luc+ 
Clone number RLU / 10.000 cells 
# 1 62.228 
# 2 510.535 
# 3 758.370 
 
Table 2: Luciferase expression intensity of Neuro 2a Luc+ cell clones. 
The clone that was used for further experiments is highlighted in grey. It is thereafter named 
Neuro 2a Luc+. 
 
Luc2 
Clone number RLU / 10.000 cells 
# 1 82.104 
# 2 54.542 
# 3 85.794 
# 4 53.281 
# 5 64.191 
# 6 84.466 
 
Table 3: Luciferase expression intensity of Neuro 2a Luc2 cell clones. 
The clone that was used for further experiments is highlighted in grey. It is thereafter named 
Neuro 2a Luc2 
 
 
Chapter 3: Results 
 
34 
To prove the correct connection of luciferase expression to the HIF pathway in ODD Luc cell 
clones, the expression intensity of untreated cells was compared to the expression intensity of 
cells treated with 100 mM deferoxamine for 24 hours prior to lysis (Table 4). Deferoxamine 
treatment leads to an intracellular iron depletion, which subsequently inhibits the activity of 
the PHD enzymes and thereby causes an inhibition of HIF degradation. 
For further experiments the cell clone with the lowest luciferase activity was selected. Those 
clones should be more sensitive to siRNA treatment due to lower luciferase mRNA levels. In 
case of the ODD Luc transgene only one clone correctly corresponded to the inhibition of HIF 
degradation by higher expression intensity of ODD Luc and was therefore selected for further 
experiments. 
 
ODD Luc 
Clone number RLU / 10.000 cells 
 
untreated 
100 mM 
deferoxamine 
# 1 5.733 5.092 
# 2 10.498 30.510 
 
Table 4: Luciferase expression intensity of Neuro 2a ODD Luc cell clones before and 
after induction by deferoxamine. 
The clone that was used for further experiments is highlighted in grey. It is thereafter named 
Neuro 2a ODD Luc. 
3.2 Characterization and optimisation of subcutaneous tumor mouse 
models  
3.2.1 Characterization of the different Luc transgenic cell clones 
To prove the ability of the selected cell clones to successfully establish subcutaneous tumors 
in mice, 1 x 106 tumor cells were injected subcutaneously into the flank of A/J mice (n = 10). 
As a positive control Neuro 2a stably expressing eGFP Luc (Neuro 2a eGFP Luc) were used. 
A subcutaneous tumor mouse model with this cell clone in A/J mice had already been 
established in our lab (data not shown). 
Tumor size was determined by caliper measurements, and luciferase expression intensity by 
bioluminescence imaging every 2 to 3 days (Figure 6 and 7). Additionally the correlation of 
bioluminescence intensity to tumor size was calculated (Figure 8). 
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Independently of the transgene tumors became palpable at around day 7 and measurable at 
around day 9 after inoculation. Thereafter they showed an exponential increase of the tumor 
volume until the experiment had to be terminated due to the tumor sizes. 
In case of expression intensity Neuro 2a Luc, Luc+ and Luc2 closely resembled the results of 
the eGFP Luc transgenic cell clone. No significant differences in expression intensity were 
detected. Bioluminescent signal was distinguishable as early as day 1 after inoculation and 
increased exponentially until the experiment was terminated. The ODD Luc transgenic cell 
clone showed a significantly diminished expression level, which remained more or less stable 
over the time of the experiment.  The last measurement revealed a slight decrease of 
expression.  
For Neuro 2a eGFPLuc and Neuro 2a Luc a direct correlation between bioluminescence signal 
and tumor volume was observed. For Neuro 2a Luc+ and Neuro 2a Luc2 the ratio between 
bioluminescence signal and tumor size decreased from day 9 to day 11 and thereafter 
remained stable. In case of Neuro 2a ODD Luc the ratio of bioluminescence signal and tumor 
volume constantly decreased over the time of the experiment. 
For clarity reason the means of the bioluminescent signals are given without standard 
deviations. 
Despite the reliable exponential growth of the bioluminescence signals as indicated by the 
mean values, there were prominent standard deviations (Figure 9). 
 
 
Figure 6: Tumor size development of the different Luc transgenic cell clones. 
Neuro 2a Luc, Luc+, Luc2 and ODD Luc respectively were examined. As a positive control 
Neuro 2a eGFP Luc was used. 1 x 106 tumor cells were injected subcutaneously into the flank 
of A/J mice (n = 10). The tumor size was determined every 2 to 3 days by caliper 
measurement and calculated as a*b*c (length*height*width). Results are presented as means 
without standard deviation. 
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Figure 7: Expression intensity of the different Luc transgenic cell clones. 
Neuro 2a Luc, Luc+, Luc2 and ODD Luc respectively were examined. As a positive control 
Neuro 2a eGFP Luc was used. 1 x 106 tumor cells were injected subcutaneously into the flank 
of A/J mice (n = 10). Expression intensity was determined every 2 to 3 days by 
bioluminescence imaging. 
Results are presented as means without standard deviation. 
 
 
 
 
Figure 8: Correlation of bioluminescence signal to tumor size of the different Luc 
transgenic cell clones. 
Neuro 2a Luc, Luc+, Luc2 and ODD Luc respectively were examined. As a positive control 
Neuro 2a eGFP Luc was used. 1 x 106 tumor cells were injected subcutaneously into the flank 
of A/J mice (n = 10). The correlation was calculated as bioluminescence signal 
(photons/second)/tumor volume (mm3). Results are presented as means without standard 
deviation. 
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Figure 9: Standard deviations of bioluminescence signals of the different Luc transgenic 
cell clones. 
Data are presented for Neuro 2a Luc (a), Neuro 2a Luc+ (b), Neuro 2a Luc2 (c), Neuro 2a 
ODD Luc (d) and Neuro 2a eGFP Luc (e). Results are presented as box plots. The boxes show 
the range of 50% of the values above and beneath the mean. The mark in the box indicates the 
overall mean. The highest and lowest bioluminescence signals are given by standard deviation 
signs. 
 
Standard deviations were especially high for the cell clones bearing luciferases with reduced 
stability, such as Neuro 2a ODD Luc and Neuro 2a Luc2. But even Neuro 2a Luc revealed 
significant standard deviations. Neuro 2a eGFP Luc and Neuro 2a Luc+ gave more or less 
robust results with a slight increase in case of Neuro 2a Luc+ after 11 days.  
As a robust basic signal has to be one of the main issues due to its impact on significance 
calculations, Neuro 2a Luc+ was chosen for further optimization.  
3.2.2 Influence of luciferin distribution on the bioluminescence signal 
Most in vivo bioluminescent measurements are carried out 10 minutes after intraperitoneal 
injection of 150 mg/kg body weight luciferin (119). It was already demonstrated, that this 
amount of luciferin does not distribute equally and is not able to saturate the enzymatic 
luciferase reaction in every location of the organism. To exclude possible artifacts, all 
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bioluminescence measurements of the present thesis are done with 300 mg/kg body weight 
luciferin according to the findings of Hildebrandt et al. (138). In one publication local 
application was described as more useful than intraperitoneal injection (120). No consent was 
found concerning the most appropriate time point of measurement after application of 
luciferin. The exact measurement protocol is discussed as being dependent on the transgenic 
tissue. 
Therefore it was necessary to check the luciferin kinetic after intraperitoneal as well as 
intravenous injection in the subcutaneous Neuro 2a Luc+ mouse model. Intratumoral injection 
was not suitable in this case due to its pathological impact on the tumor tissue. In this 
experiment also the impact of tumor vascularisation status on the luciferin uptake was 
determined. For this purpose mice bearing two tumors were used. Those mice were injected 
either intraperitoneally or intravenously with luciferin (n = 5). Directly thereafter sequence 
bioluminescence measurements were performed for 30 minutes in case of the intravenously 
injected group and for 60 minutes for the intraperitoneally injected group. 
Times after injection when maximal bioluminescence signals occurred are given in Figure 10. 
Maximal bioluminescence signals for each tumor of selected mice are presented in Figure 11. 
 
 
Figure 10: Time point of the maximal bioluminescence signal after intraperitoneal or 
intravenous injection of luciferin. 
A/J mice bearing macroscopically visible (~ 100 mm3) Neuro 2a Luc+ tumors were injected 
with 300 mg/kg body weight luciferin either intraperitoneally (a) or intravenously (b). Directly 
after injection sequence bioluminescence measurements were performed in order to determine 
the time point of the maximal bioluminescent signal. The measurement was performed over 5 
consecutive days. The results are given as box plots. The boxes cover the range of 50% of the 
values above and beneath the mean. The mark in the box indicates the overall mean. The 
highest and lowest bioluminescence signals are given by standard deviation signs. 
 
(a)
0
10
00
20
00
30
00
day 1
day 2
day 3
day 4
day 5
time after injection
(mm:ss)
(b)
0
10
00
20
00
30
00
day 1
day 2
day 3
day 4
day 5
time after injection
(mm:ss)
 
Chapter 3: Results 
 
39 
 
Figure 11: Maximal bioluminescence signals of both tumors of selected mice after 
intraperitoneal or intravenous injection of luciferin. 
A/J mice bearing macroscopically visible (~ 100 mm3) Neuro 2a Luc+ tumors were injected 
with 300 mg/kg body weight luciferin either intraperitoneally (a) or intravenously (b). Directly 
after injection sequence bioluminescence measurements were performed in order to determine 
differences in bioluminescence curves between the tumors within one animal. Measurements 
were performed over 5 consecutive days. 
The results are given as means of both tumor bioluminescence signals. Independent 
bioluminescence signals are given by the standard deviation. 
 
Interestingly the time-to-peak was almost identical for both groups (intravenous group: 13.4 
minutes; intraperitoneal group: 13.3 minutes), but the average delay between the time points 
when the first and thereafter the second tumor reached maximal levels was much smaller for 
the intraperitoneal group (< 0.3 minutes) than for the intravenous group (4.2 minutes). 
Additionally the variance between maximal bioluminescence signals which existed between 
the tumors within the same animal remained relatively stable for the intraperitoneal group but 
differed remarkably for the intravenous group. 
3.2.3 Influence of animal positioning on the bioluminescence signal 
As bioluminescent light is attenuated by traverse of tissue (107), slight differences in the 
positioning of the mouse might have an influence on the bioluminescence signal. 
To evaluate this possibility nu/nu mice (n=3) bearing two Neuro 2a Luc+ tumors were 
positioned  in the IVIS Lumina as shown in Figure 12 and subsequently the bioluminescent 
signal of both tumors was detected.  
The study showed slight changes of signal for positions, in which the tumor was not directly 
placed under the camera. 
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Figure 12: Influence of the positioning on the bioluminescence signal. 
Nu/Nu mice bearing two Neuro 2a Luc+ tumors (~ 150mm3) were placed in different positions 
during bioluminescence measurement. (A) Bioluminescence signals of one selected animal in 
accordance to its position. (B) Animals position given as an overlay of bioluminescent image 
and photograph. 
 
3.2.4 Influence of transgenic cell number on the bioluminescence signal 
As revealed above in case of the Neuro 2a Luc+ model the standard deviation of 
bioluminescence signals increased during the time course of the study whereas a good 
correlation between bioluminescence and tumor size developed. This highlights the impact of 
tumor volume divergence. From this point of view treatment during the first week after 
inoculation would be preferable, but at that point of time tumors are less than 3 mm in size and 
do not have a functional vascularisation (135), which hampers the accessibility of tumor tissue 
for systemically injected polyplexes. For this purpose tumor fragments were implanted to 
allow for better homogeneity of both, bioluminescence signal and tumor size, within the 
groups. A small (~ 2 mm) Neuro 2a Luc+ tumor fragment derived from a donor mouse was 
implanted. The development of the bioluminescence signals was observed until termination of 
the experiment (Figure 13). Additionally tumor volume of macroscopically visible tumors was 
determined by caliper measurements. 
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Figure 13: Inoculation of Neuro 2a Luc+ tumor fragments in A/J mice. 
A/J mice (n = 5) received ~ 2 mm sized Neuro 2a Luc+ tumor fragments, which were derived 
from a donor mouse. Bioluminescence measurements were performed one hour after 
inoculation, everyday over the first week and thereafter every two to four days until 
termination of the experiment. 
 
Bioluminescence signals were detectable as early as one hour after inoculation and increased 
over time. They showed a low variance over the first week, when tumors were not 
macroscopically detectable. Thereafter variance increased.  
 
 
Figure 14: Injection of Neuro 2a Luc+ cells into Neuro 2a wildtype tumors. 
A/J mice (n = 5) bearing ~ 200 mm3 sized Neuro 2a wildtype tumors were injected 
intratumorally with 1 x 106 Neuro 2a Luc+.  Bioluminescence measurements were performed 
one hour after injection and thereafter everyday until termination of the experiment. 
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In a second approach luciferase transgenic cells were injected into already existing 
subcutaneous wildtype tumors. A/J mice (n = 5) bearing Neuro 2a wildtype tumors (~ 200 
mm3) were intratumorally injected with 1 x 106 Neuro 2a Luc+ cells. Thereby a 
macroscopically visible tumor was created, which contained a defined amount (1 x 106) of 
luciferase expressing cells. The development of the bioluminescent signals was observed until 
termination of the experiment. (Figure 14) 
Bioluminescence signals were detectable as early as one hour after injection and increased 
over time. Already directly after injection a considerable variance between the animals could 
be detected.  
3.3 Utilization of mouse models for detection of effective siRNA 
delivery 
Two strategies were pursued to prove successful siRNA delivery by in vivo bioluminescence 
imaging. The first one is direct targeting of luciferase mRNA, which subsequently leads to a 
reduction of bioluminescence signal (negative readout). The second one is targeting the 
mRNA of a protein repressing luciferase activity, which thereafter results in an increase of 
bioluminescence signal (positive readout). 
Neuro 2a Luc+ was selected as negative readout system, Neuro 2a ODD Luc was evaluated as 
positive readout system. Additionally a transgenic mouse strain, expressing ODD Luc in all 
tissues, was tested. Prior to siRNA delivery studies in vivo siRNA transfer was evaluated in 
vitro. 
3.3.1 Utilization of the negative readout system (Neuro 2a Luc+) 
Different synthetic vector systems were evaluated in the A/J Neuro 2a Luc+ tumor mouse 
model regarding their siRNA delivery capacity. OEI-HD1 / Tf-OEI-HD1 (90 / 10) had already 
been proven successful in previous studies for silencing of an endogeneous gene (57), the 
other delivery systems were highly promising regarding their in vitro reporter gene silencing 
capacity. 
3.3.1.1 Tf-PLL-DMMAn-Mel-ss-siRNA 
Tf-PLL-DMMAn-Mel is an analog of the poly-L-lysine (PLL) conjugate described in Meyer 
et al. (58) containing Tf and Mel acylated with DMMAn. The modification with Tf mediates 
an effective shielding and a receptor targeting function, and the melittin peptide masked by 
DMMan provides pH-sensitive endosomolytic properties. Extracellular stability is generated 
by covalent attachment of the siRNA. Therefore this conjugate exhibits high biocompatibility 
and transfection efficacy in vitro (Figure 15). Due to low polymer yields, siRNA delivery was 
not repeated on Neuro 2a Luc+ in vitro but data of siRNA delivery on Neuro 2a eGFP Luc 
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cells are shown. These data were generated by Christian Dohmen and will be part of his PhD 
thesis. 
 
 
Figure 15: In vitro siRNA reporter gene silencing of Tf- PLL-DMMAn-Mel-ss-siRNA on 
Neuro 2a eGFP Luc. 
Five thousand cells per well were treated with the indicated amounts of target siRNA (siLuc) 
covalently attached to the polymer. Forty-eight hours after transfection cell lysis was 
performed. Gene silencing was evaluated using the luciferase reporter gene assay and toxicity 
using the MTT assay. The results are normalized to the values of untreated cells (100%).  
 
Depending on the amount of siRNA an increasing reporter gene silencing effect up to > 90% 
can be observed. In contrast, the cytotoxic effect remains relatively stable at around 20%. 
To evaluate the siRNA gene silencing capability of Tf-PLL-DMMAn-Mel-ss-siRNA in vivo, 
A/J mice bearing Neuro 2a Luc+ tumors of approximately 150 mm3 in size were used (n = 5). 
The bioluminescent signals were evaluated on two consecutive days prior to siRNA injection. 
Thereafter mice received a single intravenous treatment with 0.625 mg/kg body weight or 1.25 
mg/kg body weight target (siLuc) or scrambled (siControl) siRNA covalently attached to the 
polymer. The effects of this treatment on the bioluminescent signals of the tumors were 
measured by daily bioluminescence imaging on day 1, 2 and 4 after treatment (Figure 16). For 
clarity reasons means are given without standard deviations. Those are presented for each 
group in Figure 17.  
Due to practical reasons according to the polymer synthesis treatment with siLuc and 
siControl were performed in independent experiments. 
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Figure 16: In vivo siRNA reporter gene silencing of Tf-PLL-DMMAn-Mel-ss-siRNA on 
Neuro 2a Luc+ in A/J mice. 
A/J mice bearing ~ 150 mm3 Neuro 2a Luc+ tumors were measured over two days by 
bioluminescence imaging. Thereafter treatment was performed by intravenous injection of 
0.625 or 1.25 mg/kg body weight target siRNA (siLuc) or scrambled siRNA (siControl) 
respectively (n = 5), and the effects on bioluminescent signals were evaluated for the next two 
or four days, respectively, by daily bioluminescence imaging. Treatments with target siRNA 
and scrambled siRNA were performed in independent experiments. The day of injection is 
marked with an arrow. 
 
 
Figure 17: Standard deviations of the in vivo siRNA reporter gene silencing of Tf-PLL-
DMMAn-Mel-ss-siRNA on Neuro 2a Luc+ in A/J mice. 
The data are presented for siLuc treatment with 0.625 mg/kg body weight (a) or 1.25 mg/kg 
body weight (b) and for siControl treatment with 0.625 µg/kg body weight (c) or 1.25 mg/kg 
body weight (d). Results are presented as box plots. The boxes cover the range of 50% of the 
values above and beneath the mean. The mark in the box indicates the overall mean. The 
highest and lowest bioluminescent signals are given by standard deviation signs. 
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In all groups a decrease of the bioluminescent signal one day after treatment was detected. 
This decrease was not statistically significant. Additionally, up from the day after treatment 
the formation of non-bioluminescent areas within the tumors could be observed, which 
remained over the time of the study. These observations were made in all groups. An example 
is shown in Figure 18. 
 
 
Figure 18: Formation of non-bioluminescent areas within a Neuro 2a Luc+ tumor after 
treatment with Tf-PLL-DMMAn-Mel-ss-siRNA. 
Bioluminescence images obtained of a tumor treated with 1.25 mg siLuc/kg body weight. 
Pictures are given as overlays of the bioluminescent signal over a photograph. 
 
3.3.1.2 OEI-HD1/Tf-OEI-HD1 (90/10) 
In order to compare the newly derived bioluminescence imaging method with a carrier system 
already successfully used in the Neuro 2a tumor mouse model, gene silencing experiments 
were performed on Neuro 2a Luc+ cells in vitro and in vivo  using OEI-HD1/Tf-OEI-HD1 
(90/10) (Figures 19 and 20). 
The polymer is synthesized using OEI 800 Da (OEI) and HD as a linker, resulting in a 
biodegradable polymer with branched structure (56). 
To enhance the specific uptake by tumor cells and provide shielding, OEI-HD1 was further 
modified adding Tf as a targeting and shielding ligand (Tf-OEI-HD1). It was shown that a 
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mixture of OEI-HD1 with Tf-OEI-HD1 (w/w: 90/10) is able to promote a specific silencing of 
the targeted gene in tumor cells in vitro and in vivo in the absence of unspecific or toxic side 
effects (57). This formulation is subsequently referred to as OEI-HD1/Tf-OEI-HD1 (90/10). 
Efficacy of the treatment was shown by tumor growth retardation and tumor cell necrosis, by 
rtPCR and on the other hand by western blots of the target gene in comparison to a 
housekeeping gene.  
For in vitro experiments Neuro 2a Luc+ cells were treated with two different w/w ratios. The 
lower ratio represents the polyplexes thereafter used in the in vivo experiment exhibiting low 
toxicity, the higher ratio gives an optimal effect in vitro.  
 
 
Figure 19: In vitro reporter gene silencing of OEI-HD1/Tf-OEI-HD1 (90/10) on Neuro 2a 
Luc+. 
Ten thousand cells were treated with polyplexes containing target (siLuc) or scrambled 
(siControl) siRNA of the indicated w/w ratios. 24 or 48 hours after transfection cell lysis was 
performed. The gene silencing was evaluated using the luciferase reporter gene assay. The 
measurements were performed with n = 8, mean values of three independent experiments and 
standard deviations normalized to untreated cell (100%) are shown.  
 
While the lower w/w ratio proved ineffective after 24 as well as 48 hours, the higher w/w ratio 
mediated a reporter gene silencing effect of > 90% after 24 as well as 48 hours. However, a 
rather high reporter gene silencing in the mock treated group of 35% after 24 hours and 63% 
after 48 hours was observed indicating an unspecific effect caused by toxicity of the 
polyplexes. 
To evaluate the siRNA gene silencing capability of OEI-HD1/Tf-OEI-HD1 (90/10) in vivo, 
A/J mice bearing Neuro 2a Luc+ tumors of  approximately 150 mm3 in size were used (n = 7). 
The bioluminescent signals were evaluated on two consecutive days prior to siRNA injection. 
Thereafter mice received three consecutive intravenous treatments every 24 hours with 
polyplexes containing 2.5 mg/kg body weight target (siLuc) or scrambled (siControl) siRNA 
(w/w:0.5/1). One group remained untreated. The effects of this treatment on the 
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bioluminescent signals of the tumors were measured by daily bioluminescence imaging on day 
1, 2 and 3 after treatment (Figure 20). For clarity reasons means are given without standard 
deviations. Those are presented for each group in Figure 21. Bioluminescent signals which 
had been normalized to the pre-treatment bioluminescent signal are presented in the appendix 
(7.1). 
In contrast to siRNA delivery by bPEI Succ 10, which had been tested in parallel, no 
significant knockdown could be detected after siRNA delivery by OEI-HD1/Tf-OEI-HD1 
(90/10) (One-way-ANOVA). 
 
 
Figure 20: In vivo siRNA reporter gene silencing of OEI-HD1/Tf-OEI-HD1 (90/10) on 
Neuro 2a Luc+ in A/J mice. 
A/J mice bearing ~ 150 mm3 Neuro 2a Luc+ tumors were measured over two days by 
bioluminescence imaging. The results of these two measurements are presented as mean on 
day 1. Thereafter the treatment was performed by three intravenous injections at three 
consecutive days of 2.5 mg target siRNA (siLuc) or scrambled siRNA (siControl) respectively 
(n = 7) (w/w: 0.5/1) One group remained untreated. The effects on the bioluminescent signals 
were evaluated for the next three days by daily bioluminescence imaging. Days of injection 
are marked with arrows. 
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Figure 21: Standard deviations of the in vivo siRNA reporter gene silencing of OEI-
HD1/Tf-OEI-HD1 (90/10) on Neuro 2a Luc+ in A/J mice. 
Data are presented for siLuc treatment (a), for siControl treatment (b) or for an untreated 
group (c). Results are presented as box plots. The boxes cover the range of 50% of the values 
above and beneath the mean. The mark in the box indicates the overall mean. The highest and 
lowest bioluminescent signals are given by standard deviation signs. 
 
3.3.1.3 bPEI Succ 10 
Due to its outstanding performance in vitro (33), bPEI Succ 10 was considered a potentially 
active polymer for in vivo siRNA gene silencing and therefore tested in parallel to OEI-
HD1/Tf-OEI-HD1 (90/10) in vitro as well as in vivo (Figure 22 and Figure 23). 
It is synthesized by succinylation of 10% of the amines of bPEI, which decreases the positive 
charge of the polymer resulting in high transfection efficacy and less toxicity. 
For in vitro experiments Neuro 2a Luc+ cells were treated with two different w/w ratios. The 
lower ratio represents the polyplexes thereafter used in the in vivo experiment exhibiting low 
toxicity, the higher ratio gives an optimal effect in vitro.  
In contrast to the lower w/w ratio, which was non-toxic but less effective (~20% gene 
silencing) after 24 as well as 48 hours, the higher w/w ratio showed a specific siLuc mediated 
reporter gene silencing of ~80 % after 24 hours and even > 90% after 48 hours. It did not 
reveal any unspecific reporter gene silencing within the mock treated group after 24 hours and 
only a slight decrease after 48 hours (15%). 
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Figure 22: In vitro reporter gene silencing of bPEI Succ 10 on Neuro 2a Luc+. 
Ten thousand cells were treated with polyplexes formed of polymer and target (siLuc) or 
scrambled (siControl) siRNA in the indicated w/w ratios. Twentyfour or 48 hours after 
transfection cell lysis was performed. The gene silencing was evaluated using the Luciferase 
Reporter Gene Assay. The measurements were performed with n = 8, mean values of three 
independent experiments and standard deviations normalized to untreated cell (100%) are 
shown.  
 
To evaluate the siRNA gene silencing capability of bPEI Succ 10 in vivo, A/J mice bearing 
Neuro 2a Luc+ tumors of  approximately 150 mm3 in size were used (n = 7). The 
bioluminescent signals were evaluated on two consecutive days prior to siRNA injection. 
Thereafter mice received three consecutive intravenous treatments every 24 hours with 
polyplexes containing 2.5 mg/kg body weight target (siLuc) or scrambled (siControl) siRNA 
(w/w: 2/1). One group remained untreated. The effects of this treatment on the bioluminescent 
signals of the tumors were measured by daily bioluminescence imaging on day 1, 2 and 3 after 
treatment (Figure 23). For clarity reasons the means are given without standard deviations. 
Those are presented for each group in Figure 24. Bioluminescent signals which had been 
normalized to the pre-treatment bioluminescent signal are presented in the appendix (7.1). 
Despite the visible decrease in bioluminescent signal of the siLuc treated group and the 
unaffected increase in signal of the mock treated and untreated group, the results could not be 
proven statistically significant on the basis of the total flux data (One-way-ANOVA). 
However after normalization of the values to the pre-treatment bioluminescent signal 
(Appendix, 7.1), the siLuc treated group differed significantly from the mock treated and 
untreated group at day three and day four (p < 0.01, One-way-ANOVA). Two days after the 
last treatment the bioluminescence signal of the siLuc treated group slowly started to increase 
again. 
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Figure 23: In vivo siRNA reporter gene silencing of bPEI Succ 10 on Neuro 2a Luc+ in 
A/J mice. 
A/J mice bearing ~ 150 mm3 Neuro 2a Luc+ tumors were measured over two days by 
bioluminescence imaging. The results of these two measurements are presented as mean on 
day 1. Thereafter the treatment was performed by three intravenous injections at three 
consecutive days of 2.5 mg target siRNA (siLuc) or scrambled siRNA (siControl) respectively 
(n = 7) (w/w: 2/1). One group remained untreated. The effects on the bioluminescent signals 
were evaluated for the next three days by daily bioluminescence imaging. Days of injection 
are marked with arrows. 
 
 
Figure 24: Standard deviations of the in vivo siRNA reporter gene silencing of bPEI Succ 
10 on Neuro 2a Luc+ in A/J mice. 
The data are presented for siLuc treatment (a), for siControl treatment (b) or for an untreated 
group (c). Results are presented as box plots. The boxes cover the range of 50% of the values 
above and beneath the mean. The mark in the box indicates the overall mean. The highest and 
lowest bioluminescence signals are given by standard deviation signs. 
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To confirm these results the experiment was repeated.  This time bPEI Succ 10 was used in 
parallel to PEI (22 kDa). In order to allow for the collection of tumor samples for rtQPCR 
measurements, 14 animals were treated per group. Seven animals were euthanized 24 hours 
after the last treatment and tumors were collected. Seven animals remained for 
bioluminescence imaging, which was performed daily up to three days after the last treatment 
(Figure 25). For clarity reasons the means are given without standard deviations. Those are 
presented for each group in Figure 26. Bioluminescent signals which had been normalized to 
the pre-treatment bioluminescent signal are presented in the appendix (7.1). 
RtQPCR measurement was performed by Alexander Philipp. The data will be part of his PhD 
thesis. The amount of Luc+ mRNA was calculated in proportion to the mRNA of a 
housekeeping gene (GAPDH) (Figure 27).  
In contrast to the first in vivo experiment, in the second study no significant effect of the 
treatment by bPEI Succ 10/siRNA polyplexes could be detected. RtQPCR revealed relatively 
stable Luc+ mRNA levels for the untreated group. The ratio between Luc+ mRNA and 
GAPDH mRNA constantly (despite one exeption) ranged from 0.5 to 1. However, in the target 
as well as the mock treated groups the variance between the Luc+ mRNA levels was very 
high. The ratio of Luc+ mRNA to GAPDH mRNA varied from 0.1 to 27. No differences could 
be observed between the target and mock treated groups. 
 
 
Figure 25: In vivo siRNA reporter gene silencing of bPEI Succ 10 on Neuro 2a Luc+ in 
A/J mice. 
A/J mice bearing ~ 150 mm3 Neuro 2a Luc+ tumors were measured over two days by 
bioluminescence imaging. The results of these two measurements are presented as mean on 
day 1. Thereafter the treatment was performed by three intravenous injections at three 
consecutive days of 2.5 mg target siRNA (siLuc) or scrambled siRNA (siControl) respectively 
(n = 14) (w/w: 2/1). One group remained untreated. The bioluminescent measurement was 
performed daily up to 24 hours after the last treatment. Thereafter seven animals were 
euthanized and seven animals remained for bioluminescence imaging up to three days after the 
last treatment. 
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Figure 26: Standard deviations of the in vivo siRNA reporter gene silencing of bPEI Succ 
10 on Neuro 2a Luc+ in A/J mice. 
The data are presented for siLuc treatment (a), for siControl treatment (b) or for an untreated 
group (c). The results are presented as box plots. The boxes cover the range of 50% of the 
values above and beneath the mean. The mark in the box indicates the overall mean. The 
highest and lowest bioluminescence signals are given by standard deviation signs. 
 
 
Figure 27: Relative mRNA levels of Luc+ after treatment with bPEI Succ 10 / siRNA 
polyplexes in vivo. 
A/J mice bearing ~ 150 mm3 Neuro 2a Luc+ tumors were treated by three intravenous 
injections at three consecutive days of 2.5 mg target siRNA (siLuc) or scrambled siRNA 
(siControl) respectively (n = 14) (w/w: 2/1). One group remained untreated. 24 hours after the 
last injection mice (n = 7) were euthanized and the tumor tissue was collected. After reverse 
transcription cDNA numbers were evaluated by rtQPCR. The values of the Luc+ mRNA are 
given in proportion to the values of a housekeeping gene (GAPDH) for every animal of each 
group. 
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3.3.1.4 PEI (22 kDa) 
Linear PEI (22 kDa) was tested in parallel to bPEI Succ 10, but no samples were collected for 
rtQPCR. PEI is widely used as a DNA transfer vector due to its high transfection efficacy. In 
contrast, the siRNA delivery capacity strongly depends on the experimental design. However, 
its performance is hampered by a high toxicity. Therefore it was also used as a control for 
unspecific side effects. 
For in vitro experiments Neuro 2a Luc+ cells were treated with two different w/w ratios. The 
higher ratio represents the polyplexes thereafter facilitated in the in vivo experiment, the lower 
ratio shows the best performing polyplexes in vitro. Both ratios contained either target (siLuc) 
or scrambled (siControl) siRNA. 
 
 
Figure 28: In vitro reporter gene silencing of PEI (22kDa) on Neuro 2a Luc+. 
Ten thousand cells were treated with polyplexes formed of polymer and target (siLuc) or 
scrambled (siControl) siRNA in the indicated w/w ratios. 24 or 48 hours after transfection cell 
lysis was performed. The gene silencing was evaluated using the luciferase reporter gene 
assay. The measurements were performed with n = 8, mean values of three independent 
experiments and standard deviations normalized to untreated cell (100%) are shown.  
 
Twentyfour hours after treatment both w/w ratios demonstrated no unspecific effect in the 
mock treated groups but reasonable reporter gene silencing capacity of 80% in the siLuc 
treated groups. In contrast, 48 hours after treatment the unspecific effect in the mock treated 
groups simultaneously reached 50% while the specific effect within in the siLuc treated 
groups was > 90%. 
To evaluate the siRNA gene silencing capability of PEI (22 kDa) in vivo, A/J mice bearing 
Neuro 2a Luc+ tumors of approximately 150 mm3 in size were used (n = 7). The 
bioluminescent signals were evaluated on two consecutive days prior to siRNA injection. 
Thereafter mice received three consecutive intravenous treatments every 24 hours with 
polyplexes containing 2.5 mg/kg body weight target (siLuc) or scrambled (siControl) siRNA 
(w/w: 1/1). One group remained untreated. The effects of this treatment on the bioluminescent 
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signals of the tumors was measured by daily bioluminescence imaging on day 1, 2 and 3 after 
treatment (Figure 29). For clarity reasons the means are given without standard deviations. 
Those are presented for each group in Figure 30. The bioluminescent signals which had been 
normalized to the pre-treatment bioluminescent signals are presented in the appendix (7.1.4). 
No significant effect of the treatment by PEI (22 kDa)/siRNA polyplexes could be detected in 
vivo. 
 
 
Figure 29: In vivo siRNA reporter gene silencing of PEI (22 kDa) on Neuro 2a Luc+ in 
A/J mice. 
A/J mice bearing ~ 150 mm3 Neuro 2a Luc+ tumors were measured over two days by 
bioluminescence imaging. The results of these two measurements are presented as mean on 
day 1. Thereafter the treatment was performed by three intravenous injections at three 
consecutive days of 2.5 mg target siRNA (siLuc) or scrambled siRNA (siControl) respectively 
(n = 7) (w/w: 1/1). One group remained untreated. The effects on the bioluminescent signals 
were evaluated for the next three days by daily bioluminescence imaging. Days of injection 
are marked with arrows. 
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Figure 30: Standard deviations of the in vivo siRNA reporter gene silencing of PEI (22 
kDa) on Neuro 2a Luc+ in A/J mice. 
The data are presented for siLuc treatment (a), for siControl treatment (b) or for an untreated 
group (c). The results are presented as box plots. The boxes cover the range of 50% of the 
values above and beneath the mean. The mark in the box indicates the overall mean. The 
highest and lowest bioluminescence signals are given by standard deviation signs. 
 
3.3.1.5 PLL50- PEG-DMMAn-Mel / PLL185- PEG-DMMAn-Mel 
 Within the in vivo results obtained so far, it appeared difficult to show a significant luciferase 
knockdown. For this purpose intratumoral injection was carried out in animals bearing two 
tumors in the back, with one tumor serving as internal control to correct for variations in 
bioluminescence due to substrate distribution and other effects. In addition to bioluminescence 
imaging rtQPCR measurements were carried out. As a positive control for rtQPCR 
measurements siRan was used in parallel to siLuc. Ran had already been proven to be 
targetable in vivo in an A/J Neuro 2a wildtype model (57). In addition, the bioluminescence 
kinetic was measured to exactly determine the bioluminescent signal maximum. 
As polymers for intratumoral application of siRNA PLL50-PEG-DMMAn-Mel or PLL185-
PEG-DMMAn-Mel were chosen. Tf-PLL-DMMAn-Mel exhibited high efficacy in siRNA 
delivery together with good biocompatibility in vitro. Nevertheless the performance in vivo 
remained unclear as already mentioned above. PLL50 and PLL185 are commercially available 
PLL analogons. Modification with PLL50 or PLL185, which are PLL molecules of a defined 
chain length,  instead of PLL helps to better define the polymers. Thereby the biocompatibility 
is enhanced.  siRNA delivery was not repeated on Neuro 2a Luc+ in vitro but data of siRNA 
delivery on Neuro 2a eGFP Luc cells are shown. These data were generated by Christian 
Dohmen and will be part of his PhD thesis. Several w/w ratios were tested.  The lower ratio 
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shown in Figure 31 represents the polyplexes thereafter facilitated in the in vivo experiment, 
the higher ratio shows the best performing polyplexes in vitro. Both ratios contained either 
target (siLuc) or scrambled (siControl) siRNA (Figure 31). 
 
 
Figure 31: In vitro reporter gene silencing of PLL50-PEG-DMMAn-Mel and PLL185-
PEG-DMMAn-Mel on Neuro 2a eGFPLuc. 
Five thousand cells were treated with polyplexes formed of polymer (PLL50-PEG-DMMAn-
Mel (a), PLL185-PEG-DMMAn-Mel (b)) and target (siLuc) or scrambled (siControl) siRNA 
in the indicated w/w ratios. 48 hours after transfection cell lysis was performed. The gene 
silencing was evaluated using the Luciferase Reporter Gene Assay. Results are presented as 
means and standard deviation and are normalized to the values of untreated cells (100%).  
 
While no unspecific knockdown in the mock treated group was detectable, treatment with the 
indicated w/w ratios complexed with target siRNA resulted in a knockdown of 70 to 90 %. 
To evaluate the siRNA reporter gene silencing capability of PLL50-PEG-DMMAn-Mel and 
PLL185-PEG-DMMAn-Mel in vivo A/J mice bearing two Neuro 2a Luc+ tumors of around 
150 mm3 were used (n = 5). The bioluminescent signals were evaluated over two consecutive 
days. Thereafter mice received three intravenous treatments at three consecutive days. In every 
mouse one tumor was treated by intratumoral injection of target siRNA (siLuc), the other one 
by intratumoral injection of scrambled siRNA (siControl). PLL50-PEG-DMMAn-Mel 
polyplexes contained 1.25 mg siRNA/kg body weight in a w/w ratio of 1/1. PLL185-PEG-
DMMAn-Mel polyplexes contained 2.5 mg siRNA/kg body weight in a w/w ratio of 0.5/1. 
One group remained untreated. The effects of this treatment on the bioluminescent signals of 
the tumors were followed up to one day after the last treatment by bioluminescence imaging 
(Figure 32). For clarity reasons the means are given without standard deviations. Those are 
presented for each group in Figure 33. At the day of the last bioluminescence measurement 
tumors were explanted for further evaluation of mRNA levels by rtQPCR. (Figure 34) 
RtQPCR measurement was performed by Alexander Philipp. The data will be part of his PhD 
thesis. 
(a)
0
50
100
150
w/w: 1/1 siControl
w/w: 1/1 siLuc
w/w: 2/1 siControl
w/w: 2/1 siLuc
48 h after treatment
lu
ci
fe
ra
se
 
ac
tiv
ity
(%
 
o
f c
o
n
tr
o
l)
(b)
0
50
100
150
w/w: 0.5/1 siControl
w/w: 0.5/1 siLuc
w/w: 1/1 siControl
w/w: 1/1 siLuc
48 h after treatmentlu
ci
fe
ra
se
 
ex
pr
es
si
o
n
(%
 
o
f c
o
n
tr
o
l)
 
Chapter 3: Results 
 
57 
The treatment of the Ran targeted groups was performed analogously, but without 
bioluminescent imaging. 
No statistically significant knockdown was detected by bioluminescent imaging (One-way-
ANOVA). The mRNA measurement showed an unspecific increase of the normalized mRNA 
levels of Luc as well as Ran of the treated groups compared to the untreated group. 
Nevertheless the induction as well as the standard deviation were remarkably higher in case of 
the Luc readout. In case of Ran readout mRNA levels were more stable, but also no 
knockdown was observed. These results were independent of the housekeeping gene used for 
normalization. 
 
 
Figure 32: In vivo siRNA reporter gene silencing of PLL50-PEG-DMMAn-Mel and 
PLL185-PEG-DMMAn-Mel on Neuro 2a Luc+ in A/J mice normalized to mock 
treatment. 
A/J mice bearing two ~150 mm3 Neuro 2a Luc+ tumors were measured over two days by 
bioluminescence imaging. The results of these two measurements are presented as mean on 
day 1. The data is presented as target treated (siLuc) tumor normalized to mock treated 
(siControl) tumor bioluminescent signals. The treatment was performed by three intratumoral 
injections at three consecutive days. PLL50-PEG-DMMAn-Mel polyplexes contained 1.25 mg 
siRNA/kg body weight in a w/w ratio of 1/1. PLL185-PEG-DMMAn-Mel polyplexes 
contained 2.5 mg siRNA/kg body weight in a w/w ratio of 0.5/1. The control treatment was 
carried out within the same animal. The effects on the bioluminescent signals were evaluated 
up to one day after the last treatment by daily bioluminescence imaging. Days of injection are 
marked with arrows. 
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Figure 33: Standard deviations of the in vivo siRNA reporter gene silencing of PLL50-
PEG-DMMAn-Mel and PLL185-PEG-DMMAn-Mel on Neuro 2a Luc+ in A/J mice. 
The data are presented for siLuc treatment (a) and for siControl treatment (b). The results are 
presented as box plots. The boxes cover the range of 50% of the values above and beneath the 
mean. The mark in the box indicates the overall mean. The highest and lowest 
bioluminescence signals are given by standard deviation signs. 
 
 
 
Figure 34: Relative mRNA levels of Luc+ and Ran after treatment with PLL50-PEG-
DMMAn-Mel and PLL185-PEG-DMMAn-Mel/siRNA polyplexes in vivo. 
A/J mice bearing two ~ 150 mm3 Neuro 2a Luc+ tumors were treated by three intratumoral 
injections at three consecutive days. siLuc and siRan were used as target siRNAs, siControl as 
scrambled siRNA for mock treatment. PLL50-PEG-DMMAn-Mel polyplexes contained 1.25 
mg siRNA/kg body weight in a w/w ratio of 1/1. PLL185-PEG-DMMAn-Mel polyplexes 
contained 2.5 mg siRNA/kg body weight in a w/w ratio of 0.5/1. Control treatment was carried 
out within the same animal. One group remained untreated. 24 hours after the last injection 
mice were euthanized and the tumor tissue was collected. After reverse transcription cDNA 
numbers were evaluated by rtQPCR. Results are presented for the PLL50-PEG-DMMAn-Mel 
group (a + b) and for thePLL185-PEG-DMMAn-Mel  group (c + d), normalized to GAPDH (a 
+ c) and beta-Actin (b + d) as housekeeping genes. The values are given as means with 
standard deviation. 
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3.3.2 Utilization of the positive readout system (Neuro 2a ODD Luc) 
Two different approaches based on ODD Luc as reporter gene were followed. The first one 
was the implementation of Neuro 2a ODD Luc cells as subcutaneous tumors in A/J mice. The 
second one was an ODD Luc transgenic mouse strain expressing the transgene in every tissue.  
The overall purpose of this concept was to end up with two systems allowing to evaluate 
efficacy of siRNA delivery into the targeted tissue (ODD Luc tumors), but also in non-
targeted tissues, such as liver or lung (ODD Luc transgenic mouse strain). 
To gain an induction of the bioluminescent signal the degradation cascade of HIF1 alpha had 
to be disrupted by siRNA mediated gene silencing. Two proteins hold key positions within 
this degradation cascade and therefore were potential targets. The first one is prolyl-
hydroxylase two (PHD2). Despite being part of an enzyme family, PHD 2 has the highest 
work load. PHD2 and its family members mediate the hydroxylation of HIF1 alpha in an 
oxygen and iron depending reaction, thereby initializing the degradation cascade. 
The second one is the von-hippel-lindau-factor (VHL). As an essential part of the E3 ubiquitin 
ligase it is involved in the ubiquitination and degradation of HIF1 alpha. 
In order to test the response of the ODD Luc transgenic systems on these siRNA targets, bPEI 
Succ 10 and lipofectamine were used as delivery systems. As already pointed out in 3.3.1.3, 
bPEI Succ 10 has an outstanding position due to its high gene silencing capacity in 
combination with high biocompatibility. Lipofectamine had been proven to work sufficiently 
for siRNA delivery on fibroblasts in vitro (data not shown). 
3.3.2.1 A/J Neuro 2a ODD Luc tumor mouse model 
The response of Neuro 2a ODD Luc cells on siRNA mediated targeting of PHD2 and VHL 
was initially tested in vitro. (Figure 35) Beside the two target siRNAs, siLuc+ was used as a 
positive control in order to check for correct siRNA delivery. SiControl was facilitated as a 
negative control. Additionally one group was treated with deferoxamine. Deferoxamine causes 
iron depletion, prevents the hydroxylation of HIF1 alpha by the prolyl-hydroxylase family and 
thereby interrupts the HIF1 alpha degradation cascade. 
The data sets obtained after 24, 48 and 72 hours revealed similar results. SiRNA targeting 
Luc+ caused reporter gene silencing thereby indicating that the siRNA delivery by bPEI Succ 
10 was functional. All other siRNA treatments including the scrambled siControl resulted in 
an unspecific induction of reporter gene signal. In contrast treatment with deferoxamine turned 
out to be toxic on Neuro 2a ODD Luc cells and therefore did not show the estimated induction 
in reporter gene signal. In general standard deviations were exceptionally high. 
After these results in vitro no in vivo study was performed with Neuro 2a ODD Luc cells. 
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Figure 35: In vitro accumulation of ODD Luc fusion protein by siRNA mediated 
inhibition of HIF1 alpha degradation cascade on Neuro 2a ODD Luc. 
Ten thousand cells were treated with polyplexes formed of bPEI Succ 10 and indicated 
siRNAs. Zero point five µg siRNA/well was used in a w/w ratio of 4/1. Deferoxamine was 
used as a positive control for the system functionality. Twentyfour, 48 and 72 hours after 
transfection cell lysis was performed. The gene silencing was evaluated using the luciferase 
reporter gene assay. The measurements were performed with n = 8, mean values of three 
independent experiments and standard deviations normalized to untreated cell (100%) are 
shown.  
 
3.3.2.2 ODD Luc transgenic mouse strain 
First the response of the system on targeting of PHD2 or VHL was evaluated. Therefore 
fibroblasts were isolated from a heterozygous ODD Luc transgenic mouse (Figure 36). 
Treatment was performed as described for Neuro 2a ODD Luc cells with the exception that 
lipofectamine was used instead of bPEI Succ 10, because lipofectamine had shown higher 
efficacy in case of siRNA delivery to fibroblasts (data not shown). 
The data sets obtained after 24, 48 and 72 hours revealed similar results. Treatment with 
deferoxamine revealed a significant (p < 0.001, One-way-ANOVA) elevated luciferase signal. 
SiPHD2 treatment as well resulted in an induced signal, which became significant after 48 
hours, whereas siVHL and siControl treatment showed no effects. In contrast siLuc+ treatment 
mediated a significant reduction in reporter signal. 
In order to test if these results were as well reproducible in vivo, siPHD2 was administered to 
the liver tissue of ODD Luc transgenic mice by high pressure tail vein injection (Figures 37). 
This method is approved for delivery of naked siRNA to hepatocytes (139, 140). As a negative 
control siControl was injected. The basic bioluminescence signal of each transgenic animal 
was detected before and after siRNA treatment at several time points.  
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Figure 36: In vitro accumulation of ODD Luc fusion protein by siRNA mediated 
inhibition of HIF1 alpha degradation cascade on primary ODDLuc +/- fibroblasts. 
Five thousand cells were treated with polyplexes formed of lipofectamine and indicated 
siRNAs. Zero point five µg siRNA/well was used in an w/w ratio of 4/1. Twentyfour, 48 and 
72 hours after transfection cell lysis was performed. The gene silencing was evaluated using 
the luciferase reporter gene assay. The measurements were performed with n = 8, mean values 
of three independent experiments and standard deviations normalized to untreated cell (100%) 
are shown.  
 
 
 
Figure 37: In vivo accumulation of ODD Luc fusion protein by siPHD2 mediated 
inhibition of the HIF1 alpha degradation cascade in ODD Luc transgenic mice. 
Basic bioluminescent liver signal of ODD Luc transgenic mice was determined over some 
days. The results of these measurements are presented as mean on day 1.Thereafter the mice 
received 2.5 mL ringer-lactat-solution containing either 2.5 µg siPHD2/mL (n = 5) or 2.5 µg 
siControl (n = 2). The effects of the treatment on the liver bioluminescent signals were 
measured daily up to three days after siRNA injection. The values are given as means without 
standard deviation. The day of injection is marked with an arrow. 
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No significant difference could be detected between the target and mock treated group. Both 
groups reacted with an induction of bioluminescent signal at 24 hours after injection. At 48 
hours induction of the bioluminescent signal was even more pronounced in the target treated 
group whereas the signal in the mock treated group had already decreased. 72 hours after 
injection the bioluminescent signal of the target treated group had as well decreased, but did 
not reach basic level. 
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4 Discussion 
4.1 Generation of different monoclonal Luc transgenic Neuro 2a cell 
lines 
For the development of efficient synthetic vector systems for siRNA delivery a screening 
system is needed to test the efficacy of siRNA delivery to target cells in vivo. For this purpose 
in vivo bioluminescence imaging appeared to be the most advantageous method (61, 67, 141) 
and was therefore chosen for the experimental design. Beside the traditional negative readout 
method the development of a positive readout method was aimed. 
Firefly luciferase is known as the most useful enzyme for in vivo bioluminescence imaging 
studies due to the emitted red shifted wavelength, enzyme stability and substrate 
pharmacology. Nevertheless, different subforms of firefly luciferase vary in terms of activity 
and other parameters. (142). Therefore in the present work subtypes of firefly luciferase 
differing in expression intensity and protein stability, namely Luc, Luc+ and Luc2, were 
evaluated (134). 
As positive readout bioluminescent system a fusion construct of one of the oxygen depending 
domains (ODD) of HIF1alpha and firefly luciferase (ODD Luc) was utilized.  
Suitable plasmids were cloned in order to stably transfect tumor cells. The newly derived Luc 
encoding plasmids were initially tested for luciferase expression intensity after transient 
transfection with PEI (22 kDA) on Neuro 2a cells. As expected Luc+ exhibited no difference 
in enzyme activity compared to the positive control, which was previously reported to give 
high activity levels (137). Luc, which has not been optimized for high expression intensity, 
Luc2, which is designed to have a faster kinetic due to its degradation domains, and ODD Luc, 
which is permanently degraded under normoxic conditions, showed highly significant (p < 
0.001, One-way-ANOVA) diminished enzyme activities in comparison to Luc+. Interestingly 
ODD Luc exhibited significantly (p < 0.001, One-way-ANOVA) higher enzyme activity than 
Luc and Luc2. This high expression level of the ODD Luc fusion protein 24 hours after 
transfection with PEI (22 kDa) is most likely caused by the PEI treatment itself. PEI binds 
unspecifically to negatively charged proteins, thereby hampering their function (143). In case 
of the ODD Luc fusion protein potential interaction of PEI with one of the essential proteins 
for the degradation cascade of HIF could result in an accumulation and high activity level of 
ODD Luc fusion protein. Additionally PEI mediates transcription of immunological response 
genes and genes of many other cellular processes, such as oxidative stress responses by the 
redox-system (144). Interference with the redox system is known to have an impact on the 
activation of the HIF pathway (145, 146). This hypothesis is further supported by the fact, that 
stably transfected Neuro 2a ODD Luc cells showed basic bioluminescent signals when being 
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measured several weeks after transfection, but measurements shortly after the transfection 
revealed that they are unspecifically inducible by the treatment with transfection vectors. This 
indicates that the event of transfection causes stress and interacts with physiological cellular 
pathways in a way that activates the HIF pathway and thereby induces ODD Luc levels. 
As tumor cell line for generation of transgenic clones the murine neuroblastoma cell line 
Neuro 2a was chosen. Neuro 2a cells are known to overexpress the Tf-receptor, which allows 
for proper targeting, and to reliably lead to well vascularized subcutaneous tumors in A/J as 
well as SCID mice, which is beneficial for systemic delivery (57, 135). Additionally good 
correlation between in vitro and in vivo tests was anticipated because these cells have as well 
been used for in vitro experiments. The mean bioluminescent signals of all cell clones of each 
transgenic cell line again revealed the expected differences in signal intensity with Luc+ 
showing the highest intensity, followed by the faster degraded Luc2 and the less efficient Luc. 
As discussed above, several weeks after the transfection Neuro 2a ODD Luc cells had 
recovered to physiological conditions and therefore showed the anticipated low basic 
luciferase signal intensity. One of the Neuro 2a ODD Luc clones correctly responded to 
deferoxamine mediated inactivation of the prolylhydroxylases by an induction of the 
bioluminescent signal. 
In general there was a rather high variance in bioluminescent signal and, in case of ODD Luc, 
in respond to the deferoxamine treatment between the cell clones of each transgenic cell line. 
This variance can be explained by the random integration of one or multiple copies of 
linearized DNA into the cells genome during the transfection process. The number of copies 
as well as the integration side has an impact on the expression level as well as the functionality 
of the transgene (147-149). These effects become more distinct in monoclonal than in 
polyclonal cell lines and raise the possibility to select the cell clone which fits best in the 
experimental protocol.  
4.2 Characterization and optimization of subcutaneous tumor mouse 
models 
Subsequently the newly derived transgenic cell clones were characterized in vivo by 
evaluating the growth and the bioluminescent signal in order to assess variances compared to 
the wildtype cells that might have come along during the selection process of the transgenic 
clones. 
Additionally, the selected tumor mouse model had to be specifically adapted according to the 
demands of siRNA delivery studies. Therefore the influence of certain protocol parameters on 
the positive readout of the measurement method was checked and optimized. 
Tumor growth was found to be unhampered by the transgene. As previously reported for 
subcutaneous wildtype Neuro 2a tumors in A/J mice (35, 57), subcutaneous transgenic Neuro 
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2a clones became palpable around 7 days after inoculation and thereafter showed exponential 
increase of tumor volume until the termination of the experiment. 
Luciferase expression levels developed similarly for Neuro 2a Luc, Luc+, Luc2 and eGFP Luc 
with Luc showing slightly lower expression levels. These results were anticipated as selection 
of the clones with the lowest transgene expression already in vitro led to similar luciferase 
expression levels of all clones independently of the transgene. 
As it has also been previously reported by Dickson et al. (150), bioluminescent signals were 
distinguishable as early as day 1 after inoculation and increased exponentially according to the 
tumor growth until the experiment was terminated.  
In contrast to the negative readout systems, the positive readout system Neuro 2a ODD Luc 
revealed the desired and previously in vitro assessed low basic luciferase expression level as 
well in vivo, which remained stable over the time of the experiment. Due to the enhanced 
number of tumor cells and additionally due to the formation of hypoxic zones within the tumor 
we expected an exponential and hypoxia induced increase of expression level over the time. 
On the other hand there have been several reports on lower bioluminescent signals in larger 
tumors that could be caused by poor penetration of substrate into the tumor tissue, attenuation 
of the signal within the tumor or alteration of the transgenic status (151-153). This effect 
apparently has a higher impact on the already low basic signal of Neuro 2a ODD Luc than on 
very high bioluminescent signals such as the signals of Neuro 2a Luc+ or Neuro 2a eGFP Luc.  
However, the high variance of the data obtained by the Neuro 2a ODD Luc mouse model 
required additional in vitro experiments before utilization of this mouse model for tests of 
siRNA delivery (discussed in 4.3). 
In general standard deviations were significant and especially high for the cell clones bearing 
luciferases with reduced stability, such as Neuro 2a ODD Luc and Neuro 2a Luc2. This is not 
surprising given the fact that in these cases physiological pathways are involved in the 
degradation process of luciferase. Those are likely to be influenced interindividually over time 
thereby causing the assessed deviations. But even Neuro 2a Luc revealed notable standard 
deviations presumably due to the non optimized transcription pattern of this transgene, which 
causes an overall lower luciferase activity (134). Slight changes become more distinct in case 
of low than in case of abundant luciferase activity. Neuro 2a eGFP Luc and Neuro 2a Luc+ 
gave the most robust results. As a stable basic signal is a crucial factor for in vivo delivery 
studies further effort was done to optimize the Neuro 2a Luc+ tumor mouse model regarding 
the standard deviation. 
One critical point of bioluminescent imaging that is diversely discussed is the application 
procedure of the luciferin substrate, including amount, time point and application site (151). 
Typically, an amount of 150 mg/kg body weight luciferin is injected intraperitoneally 10 
minutes prior to bioluminescent imaging. Paroo et al. have already shown that this procedure 
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is not sufficient to evoke maximized bioluminescent signals depending on the transgenic tissue 
(119). They were able to prove that either a higher amount of substrate or local application 
into the transgenic tissue dramatically increased bioluminescent signal compared to the 
standard procedure. Therefore 300 mg/kg body weight luciferin was used in the present 
studies according to the findings of Hildebrandt et al. (138). Kayearts et al. examined the 
effect of intravenous compared to intraperitoneal substrate injection (151). They showed a 
shorter time-to-peak, a lower variance and a higher maximum bioluminescent level for 
intravenous injection offering a better reproducibility and sensitivity compared to the standard 
procedure. These results are further supported by Wang et al. (154). Nevertheless no consent 
has been found so far regarding the best time point of measurement after injection (151, 155). 
In the present study we used A/J mice bearing two subcutaneous Neuro 2a Luc+ tumors. 
Time-to-peak was almost identical after intraperitoneal and intraveneous application of 
substrate, but the interindividual variation of time-to-peak in the tumors was far lower for the 
intraperitoneally injected group than for the intravenously injected group. Additionally the 
variance between intraindividual peak signals remained relatively stable for the intraperitoneal 
group but differed remarkably for the intravenous group.  
Taken together these data indicate that in case of subcutaneous Neuro 2a tumors on the 
animals flank the substrate, which is a small molecule, reaches the tumor size over the blood 
stream and equally per diffusionem. Both distribution patterns appear to be equally fast and 
sufficient to provide the luciferase enzyme with the needed amount of substrate. Similar 
results were observed by Paroo et al., in luciferin distribution studies (119). The higher 
intraindividual delay and variance between the tumors in the intravenously treated group 
reveals a lower reproducibility compared to the intraperitoneal treated group, which stands in 
contrast to the findings presented by Kayaerts et al. (151). A possible explanation lies within 
the exclusively vascular distribution of luciferin after intravenous injection. In this case time-
to-peak depends to a higher extent onto the vascularisation level of the transgenic tumor tissue 
than in the case of distribution per diffusionem. Tumor blood vessel density as well as their 
dilatation status will consecutively have a higher influence on the time-to-peak and the peak 
level and cause higher variance between individual tumors. 
Another parameter that can influence the outcome of bioluminescent measurements is the 
position of the transgenic tissue and camera to each other. In concordance with the accepted 
assumption it could be shown in the present work that slight changes in the position can alter 
the outcome of the measurement.  
A major challenge for bioluminescent imaging of transgenic tumor tissue is the fact that tumor 
growth develops differently in each individual, which over time causes increasing 
interindividual variances. Therefore it is generally recommended to use tumors as small as 
possible. On the other hand successful systemic siRNA treatment relies on accessibility via the 
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tumor vascularisation, which is dependent on the tumor size. This conflict is solved by some 
working groups by calculation of a correction factor (105).  
In the present study a tumor mouse model with low interindividual variance in transgenic cell 
number in combination with well vascularisation was aimed at. Therefore different 
modifications of the tumor mouse model were tested. It had been shown in the literature that 
cells being injected into tumor tissue remain intact and functional (156, 157). To standardize 
all animals on a certain number of transgenic cells we therefore performed injection of a 
defined amount of transgenic cells into wildtype Neuro 2a tumors. This did not lead to less 
variance in bioluminescent signals. As the variance occurred already at the first measurement 
and persisted even over the exponential growth curve of the transgenic cells in the wildtype 
tissue, this effect is most likely caused by variances in the wildtype tumors regarding for 
example vascularisation, tissue density or necrosis, which would give rise to different 
implantation, growth and bioluminescence of the injected transgenic tumor cells.  
Another effort was made to standardize the tumor size and hence the bioluminescence signal 
by insertion of small tumor fragments. By this method the variance in bioluminescent signal 
could be significantly decreased. On the other hand it has to be taken into account that 
insertion of tumor fragments is more elaborate than injection of transgenic tumor cells - 
especially for larger groups of animals – and thus not suitable for a screening protocol. 
Therefore the standard method was used for further experiments. But the newly assessed 
method remains as a good option to standardize on tumor size and bioluminescent signal if 
needed. 
A final aspect that has to be considered in in vivo bioluminescent measurements is the 
anaesthesia stage. Anaesthesia in imaging studies is mostly done by isoflurane inhalation, 
which comes along with distribution of isoflurane throughout the whole body, diminished 
oxygen levels and lower body temperatures. Those parameters have been shown to influence 
the distribution of marker molecules (158). A standardised method of animal preparation and 
imaging was applied to limit the effects from these factors. (as described in 2.7.2.1) 
In conclusion, in the present work it has been shown that in case of the A/J Neuro 2a Luc+ 
subcutaneous tumor mouse model the optimized working protocol includes  
 intraperitoneal injection of 300 mg/kg body weight luciferin 
 time-to-measurement of 13.30 minutes or preferable sequence measurements from 10 to 
15 minutes 
 carefully positioning of the transgenic tumor tissue in relation to the camera 
 standardised anaesthesia methods 
Additionally insertion of transgenic tumor fragments came out to be a time consuming but 
highly reliable protocol to prepare tumor bearing mice for bioluminescent imaging studies. 
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4.3 Utilization of mouse models for detection of effective siRNA 
delivery 
There are only a few reports on successful siRNA delivery to tumor tissue by systemic 
injection so far. (see 1.4) This is not exceptional taken into consideration the obstacle of 
siRNA delivery itself combined with the complexicity of successful proof in vivo. Hence, 
beside the development of effective synthetic vector systems, major effort is made establishing 
an appropriate screening method. In the present study the Neuro 2a Luc+ subcutaneous tumor 
mouse model was evaluated as a very promising model for further implementation for 
detection of effective siRNA delivery as a negative readout system, as good vascularisation 
and overexpression of the Tf-receptor makes Neuro 2a cells well targetable by systemic 
siRNA delivery and Luc+ provides a stable enzyme activity. 
Additionally the Neuro 2a ODD Luc subcutaneous tumor mouse model was evaluated for the 
same purpose as a potential positive readout system. 
4.3.1 Utilization of the negative readout system (Luc+) 
Reduction of bioluminescent signal in transgenic tumor tissue by direct targeting of luciferase 
using in vivo bioluminescent imaging as the readout technique has so far successfully been 
proven only by Bartlett et al. (105, 106) However, the main focus of this working group lies 
on the development of calculation factors to correctly predict the influence of certain 
parameters such as cell doubling rate or application protocol on the mediated knockdown 
effect. Therefore they predominantly show a correlation of the predicted outcome with the 
data of single individuals, which are often corrected by calculation factors. However, 
significance tests are needed to assess the potential of new siRNA delivery vectors to induce a 
specific protein knockdown in the target tissue. In the present siRNA knockdown studies 
presumable specific as well as unspecific effects of the treatments on the bioluminescent 
readout could be shown. Treatment with Tf- PLL-DMMAn-Mel-ss-siRNA showed a clearly 
unspecific knockdown of the bioluminescent signal. Characteristic non-bioluminescent areas 
were detectable after treatment with this vector complexed with targeting as well as scrambled 
siRNA that persisted until the termination of the study. This effect might be evoked either by 
blockage of blood vessels resulting in a depletion of oxygen and luciferin within the 
vascularized tumor area or by local toxic effects of the polyplexes leading to necrosis. 
However, this phenomenon was not analyzed any further as the aim of this study was mainly 
the implementation of the mouse model and not predominantly the evaluation of the siRNA 
delivery systems. Significance could be proven for the specific knockdown of the 
bioluminescent signal following the treatment with bPEI Succ 10 delivering siLuc. However, 
these results could not be confirmed when repeating the experiment, neither by bioluminescent 
imaging nor by rtQPCR.  
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Treatment with OEI-HD1/Tf-OEI-HD1 (90/10) and PEI (22 kDa) did not reveal any visible 
knockdown effects, nor did PLL50-PEG-DMMAn-Mel or PLL185-PEG-DMMAn-Mel. 
This data highlights that verifying significance is one of the most important aspects and on the 
other hand one of the biggest hurdles.  
In significance testing a high confidence always depends on the signal-to-noise ratio and on 
the number of individuals tested. The signal-to-noise ratio thereby stands for the treatment 
mediated effect in comparison to the inherent signal variation of the readout (159).  
In order to enhance the confidence either the signal-to-noise ratio has to be improved or the 
number of animals treated per group has to be increased. As increasing the animal numbers 
cannot be an infinite option due to many – most importantly ethical – reasons optimizing the 
efficacy of the siRNA transfer vectors and eliminating the random effects on the readout 
parameter (variance of the readout parameter) has to be the major goal.  
4.3.1.1 Impact of the transfer vector 
Tf-PLL-DMMAn-Mel-ss-siRNA came out of the physicochemical and in vitro tests as a very 
promising candidate for in vivo testing. Physicochemical and in vitro data of the very similar 
PEG-PLL-DMMAn-Mel-ss-siRNA have recently been published by our working group (58). 
Nevertheless, the already published polymer still showed remarkable toxicity in vivo 
disqualifying it for further in vivo tests. Modification of the polymer with transferrin as 
targeting ligand and shielding moiety greatly enhanced biocompatibility without hampering its 
performance in physicochemical as well as in vitro tests. Hence there should be no reason for 
inefficacy in siRNA delivery in vivo. Nevertheless efficacy in vivo has not been proven using 
another method yet. 
OEI-HD1/Tf-OEI-HD1 (90/10) was previously shown to promote a specific knockdown of the 
target mRNA (Ran) in tumor cells in vitro and in vivo without unspecific toxicity (57). In vivo 
knockdown was therein confirmed by the therapeutic effect (tumor growth reduction and 
induction of apoptosis due to Ran knockdown), on the protein level by Western Blot and on 
the mRNA level by rtPCR. These findings could not be confirmed in the present work.  
Slight changes within the studies protocol could have an impact on the results. Tietze et al. 
carried out three siRNA applications every 72 hours, starting with wildtype Neuro 2a tumors 
approximately 3 mm in size. In the present study three siRNA applications every 24 hours 
were performed, and the Neuro 2a Luc+ tumors were approximately 7 mm in size. While 
Tietze et al. targeted an endogeneous gene, a transgene was targeted in the present work.  
Another aspect, that has to be taken into consideration, is the tolerated w/w ratio in vivo. This 
ratio comes out to be nearly non effective in vitro, despite the siRNA is fully complexed by 
the polymer. It has been shown in our working group recently, that free polymer is essential 
for sufficient endosomal escape of the polyplexes and consequently for siRNA delivery. 
Chapter 4: Discussion 
 
70 
(Alexander Philipp; data not published) It could be argued that there is less free polymer in in 
vivo tests and therefore polyplexes got stuck within the endosoms. On the other hand free 
polymer and polyplexes in the blood stream do not necessarily end up in the same cells (34). 
Given the fact that the same ratio has already been proven successful in vivo, this parameter 
seems to be negligible. 
bPEI Succ 10 showed an outstanding performance in vitro regarding efficacy and 
biocompatibility (33). The two independent but equally performed in vivo experiments showed 
differing results. In the first series a significant and specific knockdown effect was detectable, 
whereas in the second experiment no specific knockdown was observed. 
The reason might be that this polymer does not include any targeting moiety. While being of 
less impact regarding in vitro efficacy, targeting is known to be of extreme importance when it 
comes to in vivo performance, especially after systemic injection such as performed in the 
present study (160). This and the fact of a suboptimal w/w ratio (as discussed above in case of 
OEI-HD1/Tf-OEI-HD1 (90/10)) might hamper the effectivity of bPEI Succ 10 in vivo when 
compared to in vitro data resulting in a very low effect near the detection limit. 
For the second experiments rtQPCR data support the results that were obtained by the 
bioluminescent study, for the first experiments unfortunately no rtQPCR readout was 
performed.  
PEI (22 kDa) exhibits rather high unspecific toxic effects in proportion to the specific 
knockdown in vitro. Its effectivity for siRNA delivery has recently been investigated in vitro 
as well as in vivo (38, 161, 162). Nevertheless its performance might be hampered, because it 
does not have a targeting moiety and additionally sticks to the reticuloendothelial organs such 
as lung and liver.  
PLL50-PEG-DMMAn-Mel and PLL185-PEG-DMMAn-Mel are very similar to PLL-PEG-
DMMAn-Mel, but are - due to the exchange of undefined PLL to PLL with a certain chain 
length (PLL50, PLL185) - better defined and hence supposed to be better biocompatible. As 
intratumoral injection in a mouse model bearing two Neuro 2a Luc+ tumors was planned and 
the polyplexes were not assumed to end up in circulation, modification of these polymers with 
a targeting ligand as well as conjugation of the siRNA to the polymer were skipped. But it 
could be proven by Meyer et al. (58) that intratumoral injection of PLL- PEG-DMMAn-Mel-
ss-siRNA in Neuro 2a tumors due to the distinguished vascularization consecutively leads to 
systemic distribution. Hence PLL50-PEG-DMMAn-Mel and PLL185-PEG-DMMAn-Mel 
could as well have been distributed throughout the body. On the one hand they could – 
without a targeting moiety - not specifically attach to the tumor tissue on the other hand these 
polyplexes might be subject to fast dissociation in the blood stream. Therefore without 
targeting and conjugated siRNA payload, no specific effects can be presumed after entrance 
into the circulation. Additionally both tumors within one mouse had been treated, the first one 
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with target siRNA, the second one with scrambled siRNA. Given the event of systemic 
distribution of target as well as scrambled polyplexes the effects could possibly have been 
neutralized.  
Beside the individual aspects, that have to be considered, in general the higher dilution of the 
polyplexes within the bloodstream compared to the situation in the cell culture medium can 
have an impact on the performance. In principle, in vitro data and in vivo data are hardly 
comparable. Therefore an evaluated in vivo screening method would be needed to precisely 
assess the performance of the newly developed tumor mouse models. 
4.3.1.2 Impact of the measurement method 
As described above inherent signal variations of the readout parameter can influence the 
reliability of the resulting data. The A/J Neuro 2a Luc+ tumor mouse model reveals such 
inherent variances in the bioluminescent readout caused for example by intrinsic 
inhomogenities in the group due to tumor size or vascularisation level or by minor changes 
within the measurement protocol. Despite the effort that was made in order to precisely 
optimize and thereafter perform the measurement protocol as discussed in 4.2, variances could 
not be diminished in the utilization studies.  
They seemed to be randomly affected by mock as well as targeted treatments. This assumption 
was further supported by the rtQPCR data, which revealed an unspecific effect – both 
inductive and reductive – on the Luc+ mRNA levels after treatment with bPEI Succ 10, 
whereas the mRNA levels of untreated animals were stable. After treatment with PLL50-PEG-
DMMAn-Mel and PLL185-PEG-DMMAn-Mel Luc+ mRNA levels were induced 
unspecifically in comparison to the untreated group. This effect was detectable to a far less 
extent for the Ran mRNA levels. This difference between unspecific effects on the expression 
of a transgene or of an endogeneous gene could be explained as follows. 
Transfection efficacy with synthetic vectors is relatively low when compared to the viral 
transfection and stably integration of the transgene occurs only in rare cases. Even stably 
transgenic cells very likely loose their transgene if not constantly kept under selection 
pressure. While this is not a major concern in vitro maintenance of selection pressure is not 
easily possible in vivo. Therefore there is a reasonable chance that some of the tumor cells will 
loose their transgene during the phase of the exponential growth of the tumor. Depending on 
the number of cells and the time-point of this event, those “wildtype” cells will distort the 
readout. A mixed tissue of “wildtype” and transgenic tumor cells could explain the higher 
variance of luciferase to housekeeper ratio in comparison to Ran to housekeeper ratio in 
rtQPCR. However, the unspecific perturbation of the bioluminescent signals as well as the 
Luc+ mRNA levels after any treatment is not explainable by a mixed culture. 
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A reason for this could be the influence of the promoter. In Neuro 2a Luc+ the transgene is 
controlled by the CMV promoter. This promoter is known to be highly susceptible to silencing 
in vivo (163-165). The enhancement of CMV promoter activity was shown to be - amongst 
others - mediated by NFκB (166-168). NFκB is connected to the immune system and known 
to be activated by certain growth factors, cytokines (for example TNF alpha, IL-1beta) and 
antigens, such as double-stranded RNA (169-171) By those stimuli a strong activation or even 
reactivation of the CMV promoter after silencing is mediated by intervention of NFκB (172). 
Consequently every treatment that is able to induce the immune system might induce NFκB 
and therefore activate or reactivate the CMV promoter. 
Given the fact that the luciferase transgene itself causes antibody formation, which means 
immune stimulation, the CMV promoter is subject to constant inactivation, reactivation and 
hyperactivation. Taken the several other transcription factors into account that are involved in 
mediation of the promoter activity such as CREB/ATF, NF-1 (173), AP-1 (167), SP 1 (174) 
and MDBP (175, 176) the influence of the polyplex treatment on these transcription factors 
cannot be predicted. Therefore every transgene expression which is driven by the CMV 
promoter will be subject to unpredictable changes in vivo, especially after interference with the 
immune system or cellular signalling pathways, for example by polyplex treatment. This 
consequently disqualifies CMV promoter driven luciferase as a tool for proof of successful 
siRNA delivery. 
Summarizing the implementation studies of the negative readout tumor mouse model, it 
became apparent that it was mostly not possible to significantly prove the efficacy of the 
tested synthetic siRNA delivery vectors. Significant results could either be obtained by 
optimization of the transfer vectors performance or by eradication of the random variance of 
the models basic signal. 
As the performance of the transfer vectors naturally is not predictable and even lower efficacy 
should be detected, suppression of the basic signal variance had to be aimed at. 
This goal cannot be reached using the A/J Neuro 2a Luc+ model, because the CMV promoter 
is influenced by a variety of physiological pathways and drives luciferase expression in a 
random pattern. 
Even if the Luciferase transgene construct provided a stable signal without variance, the 
evaluation of knockout after systemic in vivo delivery would be difficult. Established tumor-
targeted transfection systems usually reach only a small fraction of the target tumor (2, 177). 
While in case of DNA delivery studies the introduction of luciferase genes into few (e.g. 10%) 
of the wildtype tumor cells would result in a very strong luciferase signal, a similar (e.g. 10%) 
reduction of luciferase in a transgenic tumor would hardly be measurable. Therefore positive 
readout systems, where silencing induces (not reduces) luciferase, are required (see next 
section). 
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4.3.2 Utilization of the positive readout system (ODD Luc) 
Induction of bioluminescent signal in transgenic tumor tissue by siRNA mediated targeting of 
a repressor protein of luciferase using in vivo bioluminescent imaging as the readout technique 
has not been proven so far. In the present studies two different approaches based on ODD Luc 
as reporter gene were followed. The first was the implementation of Neuro 2a ODD Luc cells 
as subcutaneous tumors in A/J mice. The second was the evaluation of an existing ODD Luc 
transgenic mouse strain expressing the transgene in every tissue.  
4.3.2.1 A/J Neuro 2a ODD Luc tumor mouse model 
SiRNA delivery tests in vitro using bPEI Succ 10 as a transfer vector were conducted to assess 
the inducibility of the Neuro 2a ODD Luc cells by the specific knockdown of certain essential 
proteins of the HIF1alpha degradation cascade. They revealed an unspecific inducibility of the 
system independently of the siRNA sequence. This effect was covered by a pronounced 
knockdown effect when the luciferase was directly targeted by siLuc+. In contrary, targeting 
essential proteins of the degradation cascade could not mediate a further induction compared 
to the treatment with scrambled siRNA. 
As discussed above treatment with PEI (22 kDa) had already shown inducibility of the Neuro 
2a ODD Luc system by the treatment itself. In the present study this effect was as well 
observed for the treatment with bPEI Succ 10, which is a modification of bPEI. Hence it is 
very likely that the same mechanisms – namely interaction with essential proteins, mediation 
of gene transcription and activation of oxidative stress responses – are responsible for the 
unspecific signal induction. 
Additionally treatment with deferoxamine should assess the correct inductive response of the 
ODD Luc system to interruption of the degradation cascade. Deferoxamine causes a depletion 
of iron (178). Because iron is an essential cofactor of the prolylhydroxylases, they are 
inactivated, and the degradation cascade is stopped. This effect could not been proven as 
deferoxamine turned out to be toxic on Neuro 2a ODD Luc cells. Lee et al. as well observed 
toxicity of deferoxamine on neuronal cell lines and found it to be independent of the iron 
depletion but due to the production of hydroxyl radicals and intracellular Ca2+  release (179). 
Taken together the unspecific inducibility in vitro and the random signal variances within the 
untreated A/J Neuro 2a ODD Luc tumor mouse model in vivo, this model was not used for 
further implementation in siRNA delivery studies.  
4.3.2.2 ODD Luc transgenic mouse strain 
Primary fibroblasts derived from a heterozygous ODD Luc transgenic mouse were used for 
first in vitro siRNA delivery tests.  
In contrast to the Neuro 2a ODD Luc cells, in ODD Luc fibroblasts treatment with 
deferoxamine was well tolerated, and the cells responded with a pronounced induction of 
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bioluminescent signal as it had been described by Safran et al. (133). In accordance with the 
effects observed on Neuro 2a ODD Luc, treatment with siLuc+ resulted in a clear reduction of 
the bioluminescent signal, whereas scrambled siRNA did not mediate any effect. 
Most importantly the ODD Luc fibroblasts could be shown to be inducible by knockdown of 
PHD2, but not by knockdown of VHL. Wu et al. already discussed that specific silencing of 
PHD2 is sufficient for stabilizing HIF1alpha and increasing its transcriptional activity (131). 
In the present study this could as well be proven for the ODD Luc fusion protein.  
In contrary it was surprising, that treatment with siRNA targeting VHL should not interrupt 
the HIF 1alpha degradation cascade and cause a signal induction. 
It is well known, that knockout of VHL in different cell lines leads to accumulation of HIF 
1alpha comparable to hypoxic conditions (180). Meanwhile it is frequently discussed, that 
VHL additionally plays its role within many physiological pathways. VHL has been 
implicated in extracellular-matrix formation as well as in stabilisation of the cellular 
microtubules (181, 182). Particularly in case of murine fibroblasts VHL depletion has been 
shown to impair growth (183), initialize a senescence program (184) and cause spindle 
misorientation and chromosomal instability (185). Those results indicate that beside 
accumulation of HIF 1alpha versatile effects can be mediated by VHL depletion which seem 
to have variable impacts on different cell lines. With respect to murine fibroblasts – as have 
been used in the present study – VHL depletion resulted in severe intervention with cell 
growth and viability. Such a condition – despite sublethal – could definitely have an impact on 
expression and accumulation of the ODD Luc fusion protein.  
In summary, PHD2 came out to be a promising target for further investigation in vivo. 
siRNA delivery in vivo was performed by hydrodynamic delivery of the naked siRNA into the 
animals. This technique resulted in an unspecific induction of bioluminescent signal, as had 
been observed similarly in Neuro 2a ODD Luc cells. 
Hydrodynamic delivery is known to be a highly efficient method for delivery of naked siRNA 
predominantely to the liver (139, 140, 186). On the other hand damage of liver cells has been 
reported that naturally comes with the large volume injected. Increase of ALT serum levels 
indicating the cellular damage became apparent 20 minutes after injection and dropped 
significantly 24 hours after injection (187-189). Coming along with this cellular damage an 
immunogenic reaction occurs, which on the one hand can interfere with the cellular redox-
system and on the other hand with the CMV promoter of the transgene. Intervention with the 
redox-system could mediate an induction of the bioluminescent signal by activation of the HIF 
1alpha pathway, whereas dysregulation of the CMV promoter due to immunogenic stimuli 
would lead to diverse transgene expression. A connection of the cellular damage to the 
unspecific induction of the bioluminescent signal is further supported by the fact, that the 
induction of the mock treated group lasted for 24 hours after injection, whereas the induction 
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of the target treated group was even increased after 48 hours. This indicates that there is a 
specific signal induction which is partly covered by an unspecific induction coming along with 
the liver damage.  
This in general proves the positive readout system functional. However, overall it has to be 
stated, that the high sensitivity of this system to physiological parameters such as oxygen 
saturation, immunogenic responses and cellular pathways hampers its utility for siRNA 
delivery studies. 
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5 Summary 
Nucleic acid-based therapy holds tremendous promise in the treatment of many genetic and 
acquired diseases by delivering therapeutic nucleic acids into patients.  Within nucleic acid-
based therapy a tool that has newly emerged but has already gained high importance is siRNA 
mediated therapy. 
As siRNA is subject to fast degradation in the blood stream when being injected unprotected, 
the employment of the siRNA technology for therapeutic settings requires the development of 
effective siRNA delivery vector systems. In order to optimize the delivery vectors an in vivo 
screening method for the proof of efficacy of the newly modified vector system is urgently 
needed. 
Bioluminescence imaging using firefly luciferase as the light emitting enzyme is considered 
the most advantageous technique for this purpose. Nevertheless the measurement protocol as 
well as the employment of firefly luciferase faces many problems, especially in transgenic 
tumor models. The accurate selection of the appropriate transgene and the careful adaptation 
of the tumor mouse model to the specific demands of siRNA delivery studies are crucial steps 
within the developmental process towards an appropriate in vivo screening method. 
This thesis aimed at the establishment of tumor mouse models based on firefly luciferase 
expressing murine neuroblastoma cells where siRNA triggered silencing should either reduce 
(negative readout system) or induce (positive readout system) the luciferase signal in the 
tumor. For the negative readout system, firefly luciferase enzymes that differ regarding 
expression intensity and half-life (Luc, Luc+, Luc2) were evaluated. A fusion product of an 
oxygen-sensitive HIF1 alpha fragment and firefly luciferase (ODD Luc) was tested as positive 
readout system. For this purpose also an available transgenic mouse strain (FVB ODD Luc) 
was tested expressing this hypoxia-inducible firefly luciferase system in every tissue. 
The plasmids encoding for the appropriate transgenes under the control of the CMV or SV40 
promoter were at first tested on expression intensity and thereafter stably transfected on Neuro 
2a cells. Subsequently the newly derived transgenic cell clones were characterized in A/J mice 
regarding tumor growth capacity and development of the bioluminescent signal. The A/J 
Neuro 2a Luc+ subcutaneous tumor mouse model which came out as the most reliable system 
was chosen for further optimization and implementation for siRNA delivery studies. 
Additionally the A/J Neuro 2a ODD Luc subcutaneous tumor mouse model was utilized. 
Effort was made to discover proper siRNA target genes (PHD2, VHL) for specific induction 
of this system in case of successful siRNA delivery. 
Optimization studies revealed the importance of a standardized anaesthesia protocol and 
animal positioning. For the generation of reproducible data also the timing of the 
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intraperitoneal application of the substrate with an appropriate distribution time of 13 minutes 
was important.  
In vivo studies using the negative readout system revealed, that despite the optimized 
measurement protocol the performance of the system is still hampered by a high random 
variance of the basic bioluminescent signal. This variance could to a high extent be caused by 
a dysregulation of the CMV promoter towards various experimental treatments, thereby 
unspecifically modulating the in vivo transcription of the transgene.  
Implementation studies using the positive readout system demonstrated a too high extent of 
RNAi-independent, unspecific induction of the hypoxia-responsive Neuro 2a ODD Luc tumor 
system in respond to various treatments.  
For the ODD Luc transgenic mouse strain inducibility of the system in case of siRNA 
mediated knockdown of PHD2 (but not in case of VHL knockdown) could be shown on 
primary ODD Luc fibroblasts in vitro. In vivo this effect was partly hampered by an unspecific 
induction of the bioluminescent signal. This result was mainly due to the rather rough 
technique of hydrodynamic delivery of siRNA to the liver. In summary, the positive readout 
system was functional but too sensitive to disturbances of physiological parameters to be 
successfully employed for siRNA delivery studies. 
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6 Zusammenfassung 
Durch die Anwendung von nukleinsäurebasierten Therapieformen verspricht sich die 
biomedizinische Forschung gewaltige Fortschritte bei der Behandlung von angeborenen sowie 
erworbenen Krankheitsbildern. Die Anwendung von siRNA ist ein in diesem Gebiet neu 
entwickelter jedoch bereits sehr wichtiger Ansatz. 
Da ungeschützt in den Blutstrom eingebrachte siRNA sehr schnell degradiert wird, kommt der 
Entwicklung von Transfervektoren für den Transport von siRNA eine große Bedeutung bei 
der Implementierung dieser Technik für Therapieansätze zu. Um die Effektivität der neu 
entwickelten oder modifizierten Transfervektoren im Organismus testen zu können, wird 
dringend eine in vivo Screeningmethode benötigt. 
Hinsichtlich dieses Ziels hat sich die biolumineszente Bildgebung auf Basis der Lichtemission 
der Firefly Luciferase als am ehesten zielführend erwiesen. Trotzallem ist selbst diese Technik 
bezüglich des genauen Messprotokolls und des verwendeten Luciferaseenzyms 
problembehaftet – insbesondere bei der Anwendung in Tumor-Maus-Modellen. Deshalb sind 
sowohl die sorgfältige Auswahl des geeigneten Transgenes als auch die exakte Anpassung des 
Messprotokolls an die Ansprüche beim Nachweis von siRNA Transfer äußerst wichtige 
Schritte innerhalb des Entwicklungsprozesses eines in vivo Screeningverfahrens. 
In der vorliegenden Arbeit wurde parallel die Entwicklung eines Systems mit reduziertem 
biolumineszenten Signal nach erfolgreichem siRNA Transfer sowie eines Systems mit 
induziertem biolumineszenten Signal vorangetrieben. Beide Systeme wurden in Form von 
subkutanen Tumor-Maus-Modellen etabliert. Im Fall des induzierbaren Systems wurde 
zusätzlich ein transgener Mäusestamm getestet. 
Als reduzierbares System wurden verschiedene Formen der Firefly Luciferase, die sich 
hinsichtlich ihrer Expressionsaktivität sowie der Halbwertszeit unterscheiden, herangezogen. 
Das induzierbare System basierte auf einem Fusionsprodukt des sauerstoffabhängigen 
Fragments von HIF1 alpha mit der Firefly Luciferase. 
Entsprechende für diese Transgene kodierende Plasmide wurden zunächst hinsichtlich ihrer 
Expressionsaktivität überprüft und dann stabil in das Genom von murinen Neuroblastomzellen 
integriert. 
Im Folgenden wurden die neu gewonnenen transgenen Zellklone als subkutane Tumoren in 
A/J Mäusen etabliert und auf Wachstumsrate sowie Entwicklung des biolumineszenten 
Signals überprüft. 
In diesen Versuchen stellte sich das subkutane A/J Neuro 2a Luc+ Model als am 
zuverlässigsten hinsichtlich des biolumineszenten Basissignals heraus und wurde daher für die 
weitere Optimierung sowie erste Anwendungsversuche für siRNA Transferstudien 
herangezogen. Zusätzlich wurde auch die Anwendung des subkutanen A/J Neuro 2a ODD Luc 
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Modells weiter vorangetrieben. In diesem Zusammenhang wurde besonderer Augenmerk auf 
die Evaluierung geeigneter Zielgene (PHD2, VHL) zur Induktion des biolumineszenten 
Signals nach erfolreichem siRNA-basiertem Knockdown gelegt. 
In den Optimierungsstudien konnte gezeigt werden, dass der strengen Einhaltung eines 
gleichbleibenden Narkoseprotokoll sowie einheitlicher Lagerung der Tiere eine große Rolle 
bei der Auswertbarkeit der Ergebnisse zukommt. Intraperitoneale Injektion eines 
Überschusses an Substrat und entsprechend lange Distributionszeit von 13 Minuten erwiesen 
sich als wichtig für die Generierung maximaler Biolumineszenzsignale. 
Erste Anwendungsstudien mit dem reduzierbaren System legten offen, das die 
Aussagefähigkeit dieses Systems trotz sorgfältiger Anpassung des Messprotokolls noch immer 
durch die hohe Schwankungsbreite des Grundsignals beeinträchtigt wird. Da diese 
Schwankungsbreite höchstwahrscheinlich durch eine Dysregulation des CMV Promotors, der 
die Ablesung des Transgenes steuert, ausgelöst wird, ist eine weitere Verbesserung des 
Models ausgeschlossen. 
Bei den ersten Anwendungsstudien des induzierbaren Modells in vitro wurde für die Neuro 2a 
ODD Luc Zellen eine unspezifische Induzierbarkeit des biolumineszenten Signals durch die 
Behandlung festgestellt. 
Auf den primären ODD Luc transgenen Fibroblasten, die wir für erste in vitro Versuche aus 
der transgenen Mauslinie gewonnen hatten, konnte eine Signalinduktion durch siRNA-
basierten  Knockdown der PHD2 (nicht aber durch Knockdown von VHL) erreicht werden. 
Dieser Effekt wurde jedoch bei der nachfolgenden Anwendung in vivo zum Teil von 
unspezifisch induktiven Effekten überlagert. Zwar war die gewählte Behandlungsmethode des 
Einbringens von siRNA mittels Hochdruckinjektion sehr invasiv; das induzierbare System 
erwies sich aber, obgleich vom Grundsatz funktionell, auch insgesamt als zu anfällig 
gegenüber physiologischen Veränderungen, um als Nachweismethode für siRNA Transfer 
angewendet werden zu können. 
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7 Appendix 
7.1 Supplements 
 
Figure 7.1.1 In vivo siRNA reporter gene silencing of OEI-HD1/Tf-OEI-HD1 (90/10) on 
Neuro 2a Luc+ in A/J mice normalized to the basic value. 
A/J mice bearing ~ 150 mm3 Neuro 2a Luc+ tumors were measured over two days by 
bioluminescence imaging. The mean of the results of these two measurements was set as 
100% and presented on day 1. Thereafter the treatment was performed by three intravenous 
injections at three consecutive days of 2.5 mg target siRNA (siLuc) or scrambled siRNA 
(siControl) respectively (n = 7) (w/w: 0,5/1) One group remained untreated. The effects on the 
bioluminescent signals were evaluated for the next three days by daily bioluminescence 
imaging and normalized to the basic value before treatment. 
 
 
Figure 7.1.2 In vivo siRNA reporter gene silencing of bPEI Succ 10 on Neuro 2a Luc+ in 
A/J mice normalized to the basic value. 
A/J mice bearing ~ 150 mm3 Neuro 2a Luc+ tumors were measured over two days by 
bioluminescence imaging. The mean of the results of these two measurements was set as 
100% and presented on day 1. Thereafter the treatment was performed by three intravenous 
injections at three consecutive days of 2.5 mg target siRNA (siLuc) or scrambled siRNA 
(siControl) respectively (n = 7) (w/w: 2/1). One group remained untreated. The effects on the 
bioluminescent signals were evaluated for the next three days by daily bioluminescence 
imaging and normalized to the basic value before treatment. 
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Figure 7.1.3 In vivo siRNA reporter gene silencing of bPEI Succ 10 on Neuro 2a Luc+ in 
A/J mice normalized to the basic value. 
A/J mice bearing ~ 150 mm3 Neuro 2a Luc+ tumors were measured over two days by 
bioluminescence imaging. The mean of the results of these two measurements was set as 
100% and presented on day 1. Thereafter the treatment was performed by three intravenous 
injections at three consecutive days of 2.5 mg target siRNA (siLuc) or scrambled siRNA 
(siControl) respectively (n = 14) (w/w: 2/1). One group remained untreated. The 
bioluminescent measurement was performed daily up to 24 hours after the last treatment and 
the signals were normalized to the basic value before treatment. Thereafter seven animals were 
euthanized and seven animals remained for bioluminescence imaging up to three days after the 
last treatment. 
 
Figure 7.1.4 In vivo siRNA reporter gene silencing of PEI (22 kDa) on Neuro 2a Luc+ in 
A/J mice normalized to the basic value. 
A/J mice bearing ~ 150 mm3 Neuro 2a Luc+ tumors were measured over two days by 
bioluminescence imaging. The mean of the results of these two measurements was set as 
100% and presented on day 1. Thereafter the treatment was performed by three intravenous 
injections at three consecutive days of 2.5 mg target siRNA (siLuc) or scrambled siRNA 
(siControl) respectively (n = 7) (w/w: 1/1). One group remained untreated. The effects on the 
bioluminescent signals were evaluated for the next three days by daily bioluminescence 
imaging and normalized to the basic value before treatment. 
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7.2 Abbreviations 
ALT   alanine aminotransferase 
AST   aspartate aminotransferase 
bPEI   branched polyethylenimine 
BSA   bovine serum albumine 
CCD   charge-coupled device 
cDNA   complementary desoxyribonucleic acid 
CMV   cytomegalovirus 
CT   computer tomography 
DMMAn   2,3-dimethylmaleicanhydride 
DNA   desoxyribonucleic acid 
EGF   epidermal growth factor 
eGFP   enhanced green fluorescent protein 
EPO   erythropoietin 
FIH   factor inhibiting hypoxia inducible factor 
GFP   green fluorescent protein 
GTP   guanosine triphosphate 
HIF   hypoxia inducible factor 
HSV   herpes simplex virus 
iNOS   inducible nitric oxide synthase 
LDH   lactatdehydrogenase 
Mel   melittin peptide  
min   minute 
MRI   magnetic resonance imaging 
mRNA   messenger ribonucleic acid 
NIR   near infrared 
nu/nu   NMRI nude  
ODD   oxygen depending domain 
OEI   oligoethylenimine 
pDNA   plasmid desoxyribonucleic acid 
PCR   polymerase chain reaction 
PEG   polyethylenglycol 
PEI   polyethylenimine 
PET   positron emission tomography 
PHD   prolyl hydroxylase domains 
PLL   poly-L-lysine 
PLL50   poly-L-lysine with 50 lysine monomer units   
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PLL185  poly-L-lysine with 185 lysine monomer units 
RFP   red fluorescent protein 
RISC   ribonucleic acid induced silencing complex 
RNA   ribonucleic acid 
rtQPCR  real time quantitative polymerase chain reaction 
SCID   severe combined immunodeficiency 
sec   second 
siRNA   short interfering ribonucleic acid 
shRNA   short hairpin ribonucleic acid 
SPECT   single photon emission computed tomography 
SPIO   super-paramagnetic iron oxide 
SV   simian virus 
Tf   transferrin 
TNF alpha  tumor necrosis factor alpha 
QD   quantum dot 
VEGF   vascular endothelial growth factor 
VHL   von Hippel-Lindau factor 
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